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Abstract 
 
Understanding of human immunodeficiency virus (HIV), productive viral entry, and 
its inhibition is important to elucidate viral pathogenesis and further develop therapeutics 
that is aimed to block HIV entry to CD4+ T cells. Although direct fusion with the plasma 
membrane has been long thought to be the pathway for HIV-1 entry, this notion has been 
challenged recently by various studies. In this thesis, we focus on the cellular pathways 
that lead to productive infection and mechanisms of its inhibition by membrane-
impermeable fusion inhibitors, using fluorescently-labeled HIV as an important tool. 
Although there have been many studies using fluorescently-labeled virions, understanding 
of their features in terms of infectivity, labeling efficiency, or intensity profiles has been 
limited. The results from our study characterizing single-cycle replicative, fluorescently-
labeled HIV-1 give us better understanding of HIV-1 and interpretation of data when using 
virions for further mechanistic studies. Using the characterized HIV-1, we determine to 
investigate entry pathways that lead to productive HIV-1 infection by seeking the potential 
correlation between the inhibition of cell endocytosis and the inhibition of HIV-1 infection. 
Possible scenarios for productive viral entry are direct fusion at cellular plasma membrane, 
fusion with endosomes, or both. The results from three different cell lines with various 
inhibitors that are known to block various steps of endocytosis suggest that endocytosis 
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can indeed lead to productive infection, as revealed by the specific inhibition of HIV-1 
infection by dynamin I K44A mutant. However, endocytosis may not be the only 
productive pathway for HIV-1 infection because all these inhibition data that we have 
observed appear to be partial, which is in sharp contrast to the inhibition by T20. As a 
matter of fact, for both antibodies and T20, HIV-1 infection can be blocked close to 100%, 
indicating that these drugs are efficacious enough in vitro even though HIV can establish 
productive infection through endocytosis. These results also demonstrate that endocytosed 
virions need to fuse with endosomal membrane for productive infection. In comparison to 
direct fusion at the plasma membrane, endocytosis may allow virus to escape from 
membrane impermeable drugs. The conclusion that endocytosis can initiate productive 
infection of HIV-1 virions led us to investigate whether the presence of endocytic entry 
may reduce the efficacy of membrane-impermeable drugs of HIV-1. To test this hypothesis, 
we examined the effect of T20 on the internalization of HIV-1 and the impact of 
endocytosis on T20 efficacy. These experiments show that endocytosis has no apparent 
effect on T20 efficacy, suggesting that endocytosis does not offer measurable advantage 
for the virus to escape from membrane-impermeable T20. Taken together, these studies 
suggest that endocytosis contributes to the productive entry of HIV-1, however, the efficacy 
of T20 is not affected by viral endocytosis.  
xiv 
 
 Chapter 1. 
 
Introduction 
 
1.1. Background 
1.1.1. HIV 
The human immunodeficiency virus (HIV) is a member of genus Lentivirus, part of 
family, Retroviridae (1). They are single-stranded, positive-sense, enveloped RNA viruses. 
The viral RNA genome is converted into double-stranded DNA by a viral reverse 
transcriptase (RT) that is transported along with the viral genome in the virus particle upon 
entry into the target cell. The resulting viral DNA is then integrated into the cellular DNA 
inside cell nucleus by a viral integrase and host cofactors (2). Once integrated, the virus 
can be transcribed, producing new viral RNA genomes and viral proteins. Those are 
packaged and released from the cell and a new viral particles begin the replication cycle. 
Alternatively, the virus may become latent, allowing the virus and its host cell to evade 
from the immune system (2, 3).  
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As shown in Figure 1.1A, it is roughly spherical with a diameter of about from 120 
to 150 nm (4, 5). It is composed of two copies of positive single-stranded RNA that codes 
for both structural proteins that are found in all retroviruses and several nonstructural 
proteins unique to HIV (4). The HIV genome contains three genes, gag, pol, and env, 
encoding major structural proteins as well as essential enzymes for viral replication cycle 
as shown in Figure 1.1B, (6). These are synthesized as polyproteins which produce proteins 
for virion interior, called Gag (7), the viral enzymes (Pol) or the envelope glycoproteins 
(Env). In addition to these, HIV encodes certain regulatory (Tat, Rev) and auxiliary (Nef, 
Vif, Vpr, Vpu) proteins as well (8, 9). HIV has a 9.2 kb unspliced genomic transcript 
encoding for Gag and Pol precursors; a singly spliced, 4.5 kb encoding for Env, Vif, Vpr 
and Vpu and a multiply spliced, 2 kb mRNA encoding for Tat, Rev and Nef. Gag is 
processed into matrix (MA), capsid (CA), and nucleocapsid (NC) by a viral protease during 
virion maturation process. Pol is also initially expressed as a polyprotein that is cleaved 
into functional enzymes reverse transcriptase (RT), integrase, and protease. Envelope (Env) 
is expressed as a 160 kilodalton (kDa) polyprotein (gp160), which is cleaved into gp41 and 
gp120 within the Golgi of the infected cell. gp120 directly interacts with CD4, the viral 
receptor, while gp41 is required for virus fusion with the host cell (10). Env consists of a 
cap made of three glycoprotein gp 120 and three transmembrane gp41molecules anchoring 
the structure into the viral envelope (11, 12). This glycoprotein complex present as a trimer 
enables the virus to attach to and fuse with target cells to initiate the viral infection cycle 
(13, 14).  
 
1.1.2. Acquired immunodeficiency syndrome (AIDS) 
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HIV causes the acquired immunodeficiency syndrome (AIDS). Infected humans 
progressively fail their immune system allowing life-threatening opportunistic 
infections and cancers (15). Without treatment, average survival time after infection with 
HIV is estimated to be 7 to 9 years, depending on the HIV subtype (16). Infection with 
HIV occurs by transfering blood, semen, vaginal fluid, or breast milk (17). HIV is present 
as both free virus particles and virus within infected cells in body. HIV infects immune 
cells including CD4+ T cells, macrophages, and dendritic cells (18). Viral infection lowers 
the level of CD4+ T cells via various mechanisms, such as apoptosis of uninfected 
cells, direct killing infected cells, and killing of infected CD4+ T cells by CD8+ cytotoxic 
T lymphocytes that can recognize infected cells (19, 20). When the number of CD4+ T cell 
decreases below a critical level, the body becomes more susceptible to opportunistic 
infections due to the loss of cell-mediated immune system (21, 22).  
 
1.1.3. HIV pandemic  
Despite major advances in our scientific understanding of HIV, HIV/AIDS continues 
to persist as a globally pandemic (23). Approximately 35.3 million people are living with 
HIV globally in 2012 (24). There were about 1.8 million deaths from AIDS in 2010 (24). 
Two types of HIV have been characterized: HIV-1 and HIV-2. HIV-1 is related to viruses 
found in chimpanzees and gorillas living in Western Africa, while HIV-2 is related to 
viruses found in West African primate sooty mangabey (25). HIV-1 is more virulent and 
more infective causing the majority of HIV infections globally (26). HIV-2 has the lower 
infectivity compared to HIV-1 and HIV-2 is largely confined to West Africa due to its 
relatively poor transmission rate (27).  
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1.1.4. HIV-1 life cycle 
The infection begins when the envelope glycoprotein spikes interact with the 
receptor CD4 on viral target cells. The envelope glycoprotein of HIV-1 consists of two non-
covalently associated subunits, gp120 and gp41. The engagement of gp120 and CD4 
receptor initiates a series of conformational changes in gp41 and gp120 that lead to the 
insertion of a region of gp41 into the membrane of the host cell, and the formation of a pre-
hairpin intermediate. Further changes in the conformation of gp41 bring the viral and 
cellular membranes into close enough proximity for membrane fusion (28). Partial core 
shell uncoating facilitates reverse transcription, resulting in the pre-integration complex 
(PIC) (29). Upon import of PIC into the cell nucleus, viral DNA is then integrated into the 
cellular DNA inside cell nucleus by a viral integrase and host cell cofactors (2). The host 
RNA polymerase II (RNA Pol II) mediates the proviral transcription and viral mRNAs 
serve as templates for protein production. The viral RNA is incorporated into viral particles 
with viral protein components transcribed from host cells. A newly formed viral particle 
bud and release from the cell, which is mediated by endosomal sorting complex required 
for transport (ESCRT) complexes (30). Virus is then maturated during or after budding 
process to create an infectious viral particle (31). Each step in the HIV-1 life cycle is a 
potential target for antiviral intervention.  
 
1.1.5. Current antiviral drugs for HIV-1 
1.1.5.1. Reverse transcriptase inhibitors 
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Nucleoside or Nucleotide reverse transcriptase inhibitors are analogues of nucleoside 
or nucleotide which inhibit reverse transcription. The reverse transcriptase (RT) is 
necessary for HIV to become integrated into DNA in the nucleus of the human cell because 
it must be reversely transcribed into DNA from RNA viral genome. Since RT is a viral 
protein, which is not present in mammalian cells, it can be a selective target for viral 
inhibition. Nucleoside or Nucleotide reverse transcriptase inhibitors are chain terminators 
preventing other nucleosides or nucleotides from being incorporated into the DNA chain 
because of the absence of a 3’ OH group (32). Non-nucleoside reverse transcriptase 
inhibitors inhibit reverse transcriptase by binding to an allosteric site of the enzyme (33).  
 
1.1.5.2. Integrase inhibitors 
Integrase inhibitors block the viral integrase, which is necessary for integration of 
viral DNA into the host DNA (34).  Since integration is a critical and distinct step in 
retroviral replication, these inhibitor can prevent further spread of the virus and may be 
taken in combination with other types of anti HIV drugs to minimize resistance by the virus. 
Integrase inhibitors were initially developed for the treatment of HIV infection, but they 
could be applied to other retroviruses. 
 
1.1.5.3. Protease inhibitors 
Protease inhibitors block the viral protease enzyme necessary to produce mature 
virions upon budding from the host cells. Viral protease cleaves Gag and Gag/Pol precursor 
proteins and this cleavage is critical when immature virions proceed maturation process 
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(35, 36). Proteolytic maturation is essential for the production of infectious HIV-1 virus 
(31). Virus particles produced in the presence of protease inhibitors are defective and 
mostly non-infectious.  
   
1.1.5.4. Highly active antiretroviral therapy (HAART)   
HIV has very high genetic variability resulting from its fast replication cycle, a 
high mutation rate of replication, and recombinogenic properties of reverse transcriptase 
(37-39). Most of the mutations doesn’t offer any advantage to virus, but some of them have 
a natural selection, which triggers virus to have superiority compared to their parent and 
enable them to evade from the human immune system and antiretroviral drugs (40-42). 
When antiretroviral drugs are used improperly, multidrug resistant strains can become the 
dominant genotypes and spread very rapidly. Antiretroviral combination therapy can 
suppress HIV replication, reduce the potential spontaneous resistance mutations, and 
defend against resistance. HAART is the name given to combinational treatment regimens 
used to suppress HIV viral replication and the progression of HIV disease. The usual 
HAART regimen combines three or more different mechanistic drugs such as two 
nucleoside reverse transcriptase inhibitors and a protease inhibitor, two nucleoside reverse 
transcriptase inhibitors and a non-nucleoside reverse transcriptase inhibitor or other such 
combinations. These HAART regimens have shown decreased amount of active virus and 
are able to lower the number of active virus in some cases until it is undetectable by current 
blood testing techniques. This combinational approach makes multiple blocks to HIV 
replication and reduce the possibility of a superior mutation. If a mutation that carries 
resistance to one of the drugs being taken induces, the other drugs continue to suppress 
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reproduction of that mutation (43, 44). However, there is persistent viral replication 
carrying HIV-1 resistance, which causes subsequent failure with treatment. This 
phenomena still occurs in a substantial proportion of patients, due to genetic variability or 
other factors related to individual patients (45). HIV resistance is continuously evolving, 
making difficulties to treat HIV permanently (46).   
 
1.1.5.5. Entry inhibitor  
The envelope glycoprotein complex is indispensable to HIV-1 entry into cells by 
mediating attachment to target cells and subsequent membrane fusion. Receptor 
antagonists prevent attachment of gp120 to the receptor or coreceptor and conformational 
changes within gp41 required for membrane fusion can be blocked by fusion inhibitors. 
The first fusion inhibitor developed was peptide mimics of the HR2 (heptad repeat domain 
2) sequence of gp41 that act by competitively binding to HR1 (heptad repeat domain 1). 
T20 (Enfuvirtide/Fuzeon, Roche/Trimeris) is a 36 amino acid synthetic peptide 
corresponding to the part of gp41 amino acid sequences from the HXB2 isolate, shifted 
several residues along the HR2 sequence with respect to each other (47-53). This peptide 
inhibits virus entry by binding to the HR1 core that is formed after binding of gp120 to 
CD4 and the coreceptor, thereby blocking the subsequent formation of the six-helix bundle 
(47, 53-55). It is active in the nanomolar range against diverse HIV strains and blocks virus 
infection of cells and viral spread via cell-to-cell contact, which may be the more 
physiological route (47-53, 56). T20 has been used as a salvage therapy for patients who 
have developed a resistance issue with highly active antiretroviral therapy (HARRT), 
which is a combination of several medicines that aims to control the amount of virus in 
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patients’ body (57, 58). It was approved for clinical use in March 2003 by the US Food and 
Drug Administration (FDA) and the European Medicines Agency (EMEA).  
T20 is subcutaneously administered at the recommended dose of 90 mg twice daily 
with optimized background antiretroviral therapy, reducing the level of HIV-1 RNA in 
plasma up to 48 weeks compared with optimized background therapy alone. It shows a 
small volume of distribution (5.48L), low systemic clearance (1.4 L/h) and high plasma 
protein binding (92%). Following subcutaneous administration, it is almost completely 
absorbed, and exposure correlates almost linearly with dose over the range 45–180 mg. 
Since bioavailability is high (84.3%) and the elimination half-life (3.8 hours), it is 
recommended as twice-daily administration. The pharmacokinetic-pharmacodynamic 
relationship supports its combination therapy with other antiretroviral drugs at the 
recommended dose (59). 
The other approved entry inhibitor is Maraviroc (Selzentry, Pfizer) (60, 61). 
Maraviroc works by targeting CCR5, a coreceptor located on human helper T lymphocytes 
(62, 63). The chemokine receptor CCR5 is an essential coreceptor for most HIV strains and 
necessary for viral entry into the host cell. Maraviroc binds to CCR5, to enter 
human macrophages and T cells. Because there is another coreceptor, CXCR4, which was 
used for viral entry, an HIV tropism test should be performed to determine if this drug will 
be effective (64).  
 
1.1.6. T20 mechanism, resistance, and ongoing research 
1.1.6.1. Viral fusion machinery and proposed/potential mechanisms of T20 action 
The envelope glycoprotein of HIV-1 consists of two non-covalently associated 
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subunits, gp120 and gp41. The interaction between gp120 and the CD4 receptor initiates a 
series of conformational changes in gp41 and gp120, which leads to the insertion of a 
region of gp41 into the host cellular membrane, and the formation of a pre-hairpin 
intermediate. Further conformation changes in gp41 make the viral and cellular membranes 
be close enough for membrane fusion process. Based on the fact that T20 has a homologous 
sequence to a part of C terminal heptad region (CHR) in gp41 (65), the mechanism of T20 
was proposed that it can bind to a region of gp41 that mediates this conformational change 
from pre-hairpin intermediate to the fusion-active structure, therefore preventing 
membrane fusion and viral entry (58).  
However, T20 mechanism has not been fully revealed. There are studies showing 
that T20 can target multiple sites of gp41 and gp120, which was proved by several 
experiments. First, T20 didn’t form a stable six-helix bundle with N-peptides homologous 
to N-terminal heptad region (NHR) in gp41. Also, it didn’t inhibit the formation of a stable 
six-helix bundle. Finally, T20 efficacy was significantly lowered by peptides derived from 
the membrane-spanning domain in gp41 and coreceptor binding site in gp120 (66, 67).  
 
1.1.6.2. Potential mechanisms of T20-resistance and ongoing and future development 
of antiviral drugs targeting HIV-1 entry 
Although T20 has been used as a salvage therapy for patients who had developed a 
resistance from HAART, the fast resistance with T20 has been also reported (68). Also 
different clinical isolates showed variation in susceptibility to T20 (69, 70). T20 is still 
one of the promising antiretroviral drugs since primary resistance has not been observed, 
and thus T20-naive isolates remain clinically sensitive, leading people to investigate the 
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mechanisms of T20 resistance. Understanding of T20 resistance mechanism helps develop 
more potent and less resistant T20-like antiviral drugs.  
One of the potential mechanism is that resistance to T20 is governed by changes in 
the HR1 region of gp41, specifically in a stretch of amino acids in and adjacent to the GIV 
motif, which is amino acids 36–45 of gp41 that forms part of the binding site of T20 (69). 
The 10 amino acid motif is critical for viral fusion, and T20-resistant mutants show poor 
replication compared with wild type. There are evidences that other domains in envelope 
glycoprotein outside the HR1 domain also play a role, including HR2 domain of gp41 (69, 
71). Based on sequence analysis, mutation GIV to GIA in HR1, SNY to SKY in HR2 
domain, and double mutation in HR1 and HR2 caused T20 resistance (69, 70). Thus, there 
has been many ongoing trials to develop T20-like peptide which is designed to impact on 
the resistance phenotype as well as not to influence viral fitness based on the above 
mechanistic studies.  
Furthermore, another approach as ongoing research is improving stability and 
formulation. Although T20 is one of the potent anti HIV-1 drugs, it needs to be 
subcutaneously injected to reach a sufficiently high blood level for inhibiting viral 
infection and also causes common symptoms on the injection site (72-76). Also it has a 
short shelf-life and causes a high cost of production (58).  
Researches on the next generation of fusion inhibitors, which optimally have 
enhanced efficacy, a higher genetic barrier to resistance issue, less frequent subcutaneous 
administration, and combined with the use of new formulation methods will enlighten to 
prevent both chronic and acute viral infections (77, 78). Besides T20 and derivatives, other 
fusion inhibitors have been developed that target different domains of gp41 (65, 78, 79).   
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1.1.7. Mechanisms of HIV-1 entry 
The productive entry of HIV-1 is still controversial with different experimental 
approaches and research groups (80, 81). Productive entry of HIV-1 into CD4+ T cells is 
initiated by binding of the viral envelope gp120 to CD4 receptor. This binding causes a 
cascade of conformational changes in both the gp120 and gp41 that eventually lead to 
virus-cell membrane fusion and HIV-1 entry (28, 82). Endocytosis is an required entry step 
for enveloped viruses whose fusion proteins are activated by acidic pH (83). In contrast, 
viruses that undergo fusion upon interacting with corresponding cellular receptors 
regardless of the pH have been believed to fuse directly with a plasma membrane. 
Consistently, it was revealed that HIV-1 entry and viral membrane fusion do not require 
exposure to low pH (84). 
Early studies of HIV-1 entry have focused on the identification of receptors on T cell 
surface mediating viral productive entry. These have revealed that CD4 and chemokine 
coreceptors (CCR5 or CXCR4) are necessary for HIV entry to CD4+ T cells (85). Although 
it has not been observed directly, HIV-1 entry is long thought to be a direct fusion between 
viral membrane and T cell membrane (28, 83, 86). There are several studies supporting this 
mechanism: first of all, interaction between CD4 and envelope protein gp120 can trigger 
conformational changes to fusion-active structure (28); second, cell-cell fusion can be 
mediated by HIV envelope proteins expressed on one cell surface and receptors (87); third, 
viral entry does not require the endocytosis of its receptor CD4 nor does it depend on low 
pH, which may be necessary for viral endocytosis (88, 89); finally, electron microscopy 
(EM) images have shown the intermediates of a direct fusion between virus and cell 
membrane (90-92).  
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However, recent study using real time fluorescence imaging technology at single 
molecule level has directly shown that HIV-1 enter its target cells via dynamin-dependent 
endocytosis instead of direct fusion in TZM-bl cells (81). Consistently, viral fusion with 
endosomes and micropinosomes has been observed by EM (93, 94). Second, viral infection 
increases with blocking the acidification of endosomal compartments and apparently by 
sparing the virus from degradation in lysosomes (95-97). Third, efficient infection by 
Vesicular stomatitis virus G protein (VSV-G) pseudotyped virus (98) shows that there are 
no significant limitations associated with viral endocytosis. Lastly, inhibition of clathrin-
mediated endocytosis decreases the efficacy of virus-cell fusion and infection in HeLa-
derived cells (99).  
Possible scenarios for productive viral entry are direct fusion at cellular plasma 
membrane, endocytosis, or both.  Although direct fusion is thought to be the pathway for 
HIV-1 entry (82, 83, 86), this has been challenged recently by various studies (81, 
100).  This question is fundamentally important for molecular understanding of HIV-1 
infection. Understanding of productive HIV-1 entry will help elucidate viral pathogenesis 
and further develop therapeutics that is aimed to block HIV entry to CD4+ T cells.  
 
1.1.8. Single-cycle replicative HIV-1 
Non-capable of multiple rounds of infections but antigenic HIV-1 particles are 
essential tool for the research on many topics associated with this virus. This molecularly 
cloned HIV-1 that is capable of only a single round of infection (101, 102), e.g. single-
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cycle replicative virions, offers a unique tool to address important questions related viral 
entry and infectivity. The production of these virions in cell culture involves the use of a 
mutant provirus clone together with a separate plasmid that drives the expression of viral 
envelope glycoproteins. Because viral proteins are expressed from cloned DNA instead of 
the provirus reversed transcribed from a RNA genome by RT, mutations in viral proteins 
that arise from RT errors or APOBEC3 activity are virtually eliminated. Since cells 
infected by these single-cycle virions result exclusively from the initial input virus, the 
efficiency of provirus integration can be correlated with the efficiency of viral entry 
without complications from multiple rounds of infection (103). Although single-cycle 
HIV-1 virions have been widely used for viral neutralization assays (104) and evaluation 
of antiviral drugs (105), the features of virions in terms of size, intensity, or infectivity have 
not been extensively studied. Those will be further characterized and optimized in chapter 
1.  
 
1.2. Rationale and Significance 
1.2.1. Characterizing single-cycle replicative, fluorescently-labeled HIV-1 
Although single-cycle HIV-1 virions have been extensively used for viral 
neutralization assays (104) and evaluation of antiviral drugs (105), conditions to optimize 
their infectivity in cell culture have not been fully reported. The intensity profiles and 
labeling efficiency of fluorescently-labeled virions during virion manipulation have not 
been also extensively studied, which has been used to track the behavior of HIV-1 in the 
cytoplasm of infected cells. Because the expression of provirus, envelope glycoproteins, 
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and fluorescent proteins is separate in three plasmids and there is a possibility that not all 
three plasmids can transfect the same at equal quantity, intensity profiles of fluorescent-
tagged HIV-1 virion may show heterogeneous phenomena. Although EGFP-Vpr fusion 
protein in virions allows direct visualization, the potential presence of virions without 
EGFP may significantly complicate the study of imaging virus. Consistently, a recent study 
revealed that there is heterogeneity of HIV-1 virions in terms of viral protein composition 
with single-molecule sensitivity (5). This heterogeneity might lead to a broad spectrum of 
infectivity for individual HIV-1 virions (103), which was hypothesized in the literature 
(106). Thus, characterizing the infectivity and intensity profiles of single-cycle replicative, 
fluorescently-labeled HIV-1 will help further investigate the mechanism of viral entry as 
well as develop deep understanding of HIV-1 virions.   
 
1.2.2. HIV-1 productive entry pathway 
Productive entry of HIV-1 into CD4+ T cells has not been clearly investigated yet. 
This question is fundamentally important for molecular understanding of HIV-1 
infection.  Early studies have suggested that HIV-1 can enter target cells via direct fusion 
at the plasma membrane (96, 107, 108). In contrast, recent studies have suggested that the 
direct fusion at the plasma membrane is not productive. Instead, HIV-1 may enter cells via 
dynamin-dependent endocytosis (81, 100) and lead to a productive infection. Possible 
mechanisms for productive viral entry are direct fusion at the plasma membrane, 
endocytosis, or both. In this study, in order to determine if virion endocytosis can lead to 
productive infection, we seek to correlate the inhibition of endocytosis and inhibition of 
infection. Understanding of productive HIV-1 entry will help elucidate viral pathogenesis 
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and further develop anti HIV-1 drugs that are aimed to block HIV entry to CD4+ T cells.  
 
1.2.3. Mechanism of entry inhibitor, T20 
Both antibodies and T20 can block viral infections close to 100%, indicating that 
these drugs are efficacious enough in vitro. T20 has been used as a salvage therapy for 
patients who have developed a resistance issue with highly active antiretroviral therapy 
(HARRT), which is a combination of several medicines that aims to control the amount of 
virus in patients’ body (57, 58). Although T20 needs to be subcutaneously injected to reach 
a sufficiently high blood level for inhibiting viral infection and also causes common 
symptoms on the injection site (72-76), T20 was the first new class of HIV inhibitors 
targeting the viral entry step. T20 was therefore a promising ingredient of a therapeutic 
salvage regimen (79) since T20 action is not affected by the presence of resistance 
mutations against protease and reverse transcriptase inhibitors.  
The mechanism of T20 has been proposed that it binds to a region of gp41 that 
mediates the conformational change from pre-hairpin intermediate to the fusion-active 
structure based on its sequences homologous to C-terminal heptad repeat (CHR) region. 
Contrary to this belief, there have been several studies suggesting T20 inhibits HIV-1 entry 
by targeting multiple sites in gp41 and gp120 (57, 65). Although T20 is one of the 
promising and potent drugs, the mechanism and behavior of T20 has not been fully 
understood. Furthermore, in comparison to direct fusion at the plasma membrane, some 
studies have suggested that endocytosis may allow virions to escape from the action of 
membrane-impermeable drugs (109, 110). Thus, investigating the impact of endocytosis 
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on membrane-impermeable T20 and its mechanism is fundamentally important for 
molecular understanding of HIV-1 entry as well as developing new generations of T20-like 
anti HIV-1 drugs with improved potency and stability.    
 
1.3. Specific aims and Hypotheses  
1.3.1. Specific aim 1: Preparation and characterization of single-cycle replicative, 
fluorescently-labeled HIV-1 virions 
1.3.1.1. Varying virus culture conditions improves the infectivity of HIV-1. 
We defined infectivity as the fraction of virions that can establish a productive 
infection in a host indicator cell line by establishing how to measure the concentration of 
infectious virus particles (Ci.p.) by taking an advantage of viral protein, Vpr, suppressing 
cell cycle. We then varied virus culture conditions, such as EGFP-Vpr plasmid input, virion 
harvest time, media replacement after transfection, and envelope plasmid input.  
 
1.3.1.2. There is a trade-off effect between virion infectivity and fluorescent intensity. 
How heterogenous are the fluorescent intensities of virions? 
We tested the correlation between the number of virion particles and the 
concentration of physical particles (Cp.p.) by using custom-written MATLAB due to the 
potential presence of virions without EGFP. The labeling efficiency of HIV-1 carrying 
EGFP-Vpr was also determined. We then characterized HIV-1 tagged with EGFP-Vpr in 
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terms of size, mean intensity, and sum intensity distributions by varying EGFP-Vpr inputs. 
This would give us a rationale to pick a certain input of EGFP-Vpr, which results in the 
highest infectivity and reasonable intensity profiles for further imaging and infection 
studies. 
 
1.3.2. Specific aim 2: Determine entry pathways that lead to productive HIV-1 
infection 
1.3.2.1. Endocytosis contributes to productive viral entry. 
We tested whether there is a correlation between the inhibition on viral infection and 
the inhibition of cell endocytosis. First of all, we can clearly visualize HIV-1 virions 
colocalized with early endosomes.  For the specific inhibition on dynamin-dependent 
endocytosis, we used dynamin I K44A mutant (111), which acts as a dominant-negative 
fashion to block the formation of functional dynamin oligomers required for dynamin-
dependent endocytosis (112-114). The specificity of inhibition on endocytosis was checked 
by measuring transferrin uptake (115, 116). Also, to determine if virion endocytosis can 
lead to productive infection, various inhibitors that are known to block various steps of 
endocytosis were used. These studies were compared with VSV-G pseudotyped virions, 
which are known to enter cells through receptor-dependent endocytosis (117). 
 
1.3.2.2. Productive viral entry depends on cell types, viral envelopes from different 
strain, or facilitating virus binding method. 
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We used different cell lines, such as TZM-bl, Rev-CEM, or, SupT1 cell lines with 
dynasore and T20 to determine if virion endocytosis/fusion can lead to productive infection. 
Also, envelope glycoproteins from both NL4-3 and HXB2 strains were tested in TZM-bl 
cell line with dynasore treatment. To exclude the possibility that the inhibitory effect of 
dynasore on viral infection in the presence of DEAE-dextran or spinoculation to facilitate 
virus binding to a cell and increasing apparent infectivity (103, 118) might have nonspecific 
effect, the parallel experiments without either facilitating method were also tested in TZM-
bl cells.  
 
1.3.3. Specific aim 3: Impact of virion endocytosis on membrane-impermeable HIV-1 
drugs 
1.3.3.1. Does T20 affect virion internalization? 
     We quantitated virion internalization with different inoculation time points and 
compared its fraction between in the absence and presence of T20, whose concentration is 
able to block viral infection close to 100%. We also tested the hypothesis that we might be 
able to see the higher fraction of virion internalization with saturation concentration of T20 
due to no fusion events available. 
 
1.3.3.2. Some events of viral endocytosis come from receptor-independent endocytosis, 
which is cellular proteins-specific on virion surface. 
     We compared the fraction of virion endocytosis between HIV-1 carrying envelope 
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glycoprotein and gag particles, which doesn’t have viral envelope on virion surface. We 
also tested whether the receptor-independent phenomena come from the difference in host 
proteins on virion surface by producing virions from 293T or Jurkat T cells.   
 
1.3.3.3. Endocytosis offers an advantage for virus to escape from membrane-
impermeable peptidic inhibitor, T20.  
Endocytosis may allow virus to escape from membrane-impermeable inhibitors. 
Otherwise, fusion inhibitor, T-20, may exert its inhibitory effect inside endosome as bound 
to endocytosed HIV-1 based on the assumption that endocytosis may contribute to viral 
infection. To test the effect of endoytosis on T20 efficacy, we titrated T20 in TZM-bl cells, 
whose endocytosis had been inhibited by dynasore or dyn I K44A. We then varied time 
points T20 added during virion inoculation to see whether T20 efficacy would be different.   
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1.4. Figures   
 
 
 
Figure 1.1. Diagram and structure of viral RNA genome. 
 
(A) Diagram of HIV. This figure was from (119). (B) RNA genome structure of HIV-1. 
HIV has a 9.2kb unspliced genomic transcript which encodes for gag and pol precursors; a 
singly spliced, 4.5 kb encoding for env, Vif, Vpr and Vpu and a multiply spliced, 2 kb 
mRNA encoding for Tat, Rev and Nef. This figure was modified from (120). 
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Figure 1.2. HIV-1 life cycle and potential targets (modified from (121)). 
 
Step 1: Viral attachment with the engagement between viral gp120 and cellular CD4.  
Step 2: Membrane fusion between viral membrane and cellular membrane. 
Step 3: Viral uncoating resulting in the release of viral genome to cytoplasm. 
Step 4: Viral RNA is converted into DNA by a viral reverse transcriptase. 
Step 5: Pre-integration complex (PIC) is imported to cell nucleus. 
Step 6: Viral genome is integrated into host cell DNA by a viral integrase. 
Step 7-9: Host cell transcribes viral mRNAs, which are exported to cytosol and translated 
in cytosol  
Step 10-13: Viral genome and proteins are packaged and budded out from cellular 
membrane with maturation process by a viral protease.  
  
 
 
 
 
21 
 
 
 
 
Figure 1.3. Possible productive HIV-1 entry.   
 
Upon the engagement between HIV and CD4 receptor on cell surface, the virus can enter 
target cells through three non-exclusive pathways. The first pathway is the direct fusion of 
HIV particles at the plasma membrane. Second, HIV enters cells via receptor-dependent 
endocytosis and leads to HIV fusion with an endosome membrane, or this could lead to 
endosome maturation and lysosomal degradation of the virus particle. In the third pathway, 
coreceptor engagement might lead to virus membrane and endosome membrane fusion and 
release of the viral genome into the cytosol; alternatively, in the absence of the appropriate 
coreceptor or coreceptor independent transfer, viruses might be recycled back to the 
extracellular medium as infectious particles capable of mediating a productive infection. 
This figure was modified from (122). 
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Chapter 2. 
 
Preparation and Characterization of Single-cycle 
Replicative, Fluorescently-labeled HIV-1 Virions 
 
2.1. Abstract 
Molecularly cloned HIV-1 that is capable of only a single round of infection (1, 2), 
called single-cycle replicative virion, offers a unique tool to address important questions 
related to the early event of viral infection, such as viral entry. In this study, we established 
how to measure the concentration of infectious particles (Ci.p.) for measuring infectivity 
by taking an advantage of viral protein, Vpr, suppressing G2 cell cycle (3). The infectivity 
was then optimized by varying several virus culture conditions. Among these culture 
variables, EGFP-Vpr plasmid input, virion harvest time, media replacement after 
transfection, and envelope plasmid input can all improve HIV-1 infectivity by reducing the 
number of defective virions.  
In order to investigate viral entry, we visualized virions by tagging Vpr, a viral 
accessory protein physically associated with the virus core, with EGFP (4-6). Although the 
imaging method cannot provide a direct conversion between the number of virion particles 
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and the concentration of physical particles (Cp.p.) due to the potential presence of virions 
without EGFP, they were strongly correlated supporting p24 values as a measurement of 
viral Cp.p. in our imaging method. Furthermore, we characterized HIV-1 tagged with 
EGFP-Vpr in terms of size, mean intensity, and sum intensity distributions. Even though 
there was a trade-off effect between fluorescent intensity and infectivity, we were able to 
pick 0.15 µg/ml of EGFP-Vpr plasmid input which results in the highest infectivity and 
reasonable intensity profiles amid the broad distribution of intensities. This will help 
further investigate the mechanism of viral entry as well as develop deep understanding of 
HIV-1 virions. 
 
2.2. Introduction 
The infectivity of retroviruses such as HIV-1 in plasma or cultured media is generally 
less than 0.1% (7-12). Although there have been extensive studies about this virus over the 
past 30 years (13-19), the molecular mechanisms that underlie this apparent low infectivity 
are not fully understood. Broadly defined, two different mechanisms have been proposed 
to explain this phenomenon.  
One possible mechanism is that a large proportion of virions are inherently defective, 
with only a small portion of virions highly infectious. In other words, the average 
infectivity of a virus pool is low because of the presence of defective virions. Alternatively, 
virions are intrinsically infectious but the viral-cell interactions lead to a major barrier for 
HIV-1 infection, which limits the apparent infectivity of HIV-1 virions. Overall, recent 
studies suggested that HIV-1 virion attachment to host cells is an inefficient process, but 
once virions enter a host cell, subsequent steps can occur with a relatively high efficiency. 
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Consistently, polycations or spinoculation has been used for facilitating and increasing 
virus binding to a cell and apparent infectivity. (20, 21). This model argues against the 
presence of defective virions in a virus pool, but supports the hypothesis that HIV-1 virions 
are intrinsically infectious. However, the high infectivity of HIV-1 virions revealed from 
the above studies was for viruses that were either pre-adsorbed on host cell surface or which 
had already initiated reverse transcription. In the virus pool, there were still large 
populations of unadsorbed virions or virions that had not initiated reverse transcription. 
Whether they are defective virions, i.e., virions that are deficient in receptor engagement 
or initiation of reverse transcription remains unknown. The production of defective virions 
due to mutations results in the heterogeneity of a virus pool, which may significantly 
complicate the study of viral infectivity.  
Alternatively, single-cycle replicative HIV-1 (1, 2) allows to address these important 
questions. The production of these virions in cell culture use a mutant provirus clone 
together with a separate plasmid that drives the expression of viral envelope glycoproteins. 
Because viral proteins are expressed from cloned DNA instead of the provirus reversed 
transcribed from a RNA genome by reverse transcriptase (RT), mutations in viral proteins 
that arise from RT errors or APOBEC3 activity are virtually excluded. By varying culture 
conditions used to produce these virions, one can potentially optimize the infectivity of 
HIV-1 and address the intrinsic infectivity of these virions. Moreover, because cells 
infected by these single-cycle virions result exclusively from the initial input virus, the 
efficiency of provirus integration and that of viral entry can be correlated without 
complications from multiple rounds of infection.  
Although single-cycle HIV-1 virions have been extensively used for viral 
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neutralization assays (22) and evaluation of antiviral drugs (23), conditions to optimize 
their infectivity in cell culture have not been fully reported. The typical procedures use an 
equal weight mixture of provirus and envelope plasmids for transfection in 293 or 293T 
cells, and virions are harvested 48 hours post transfection (1). Because the expression of 
provirus and envelope glycoproteins is separate in two plasmids, the ratio between the two 
plasmids may pose the expression of Gag and envelope glycoproteins at different levels. 
As a result, the overall infectivity of virions may be different depending on the level of 
envelope protein incorporation (24, 25). Also, there has been no rationale for harvesting 
virions 48 hours post transfection. Biophysical instability of virion proteins is known to 
cause virus inactivation with time (7). This inactivation can occur simultaneously with 
virion production and thus an optimal time frame for harvesting virion from cell culture 
may be expected. Indeed, recent studies on replicative HIV-1 virions revealed that virions 
harvested at early time points from culture media have higher infectivity on a per particle 
basis (12), suggesting that HIV-1 virion infectivity may be optimized through variation in 
their culture conditions.  
To track the behavior of HIV-1 in the cytoplasm of infected cells, virions derived 
from the X4-tropic NL4-3 provirus clone were tagged internally with EGFP fused to Vpr 
(4, 5). Vpr is an accessory protein of HIV that physically associates with the virion core (6) 
and thus this fusion protein serves as a fluorescent marker (5) for virion manipulation. 
Control experiments showed that EGFP–Vpr also distinguishes virions from microvesicles 
(26). Alternatively, HIV virions carrying free EGFPs were generated by constructing the 
provirus clone that carries EGFPs between matrix and capsid proteins through two linkers 
that can be cleaved by HIV protease during the virion maturation process (27). Viral 
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membrane and free EGFPs should disappear resulting from virla fusion with the plasma 
membrane due to their virtually infinite dilution within the plasma membrane and the 
cytosol (27).  
However, a recent study revealed that there is heterogeneity of HIV-1 in terms of 
protein composition with single-molecule sensitivity (26). For gp120, its copy number 
varied over one order of magnitude, despite the fact that all these virions were derived from 
a single clone. This heterogeneity might lead to a broad spectrum of infectivity for 
individual HIV-1 virions (21), which was hypothesized in the literature (28). Indeed, recent 
studies have shown that the transmitted ‘founder’ virus that establishes infection in AIDS 
patients corresponds to virions with a higher envelope glycoprotein content (29). Because 
the expression of provirus, envelope glycoproteins, and EGFP-Vpr is separate in three 
plasmids and there is a possibility that not all three plasmids can transfect each cell, 
intensity profiles of fluorescent-tagged HIV-1 virion may show heterogeneous phenomena. 
Although EGFP-Vpr fusion protein in virions allows direct visualization, the potential 
presence of virions without EGFP may significantly complicate the study of imaging virus. 
Thus, characterizing the infectivity and intensity profiles of single-cycle replicative, 
fluorescently-labeled HIV-1 will help further investigate the mechanism of viral entry as 
well as develop deep understanding of HIV-1 virions.   
 
2.3. Materials and Methods 
Construction of plasmids   
NL4-3 is an HIV-1 strain widely used for production of cloned HIV-1 virions (30-
32). To produce single-cycle virus, we introduced a frameshift mutation within the 
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envelope coding region of the NL4-3 provirus, which resulted in premature stop codons in 
the open reading frame (ORF) for the envelope glycoprotein (31). Cotransfection of the 
mutant provirus together with envelope expression plasmid in 293T cells allows production 
of single-cycle virus. Three plasmids, pNL4-3 (cat#114), pEGFP-Vpr (cat#11386), and 
pNL4-3.Luc3.R¯E¯ (cat#3418) were obtained through the NIH AIDS Research and 
Reference Reagent Program. Briefly, to construct the provirus DNA that harbors the 
frameshift mutation in the ORF of the envelope glycoprotein, a 1509-bp DNA fragment 
between EcoRI and NheI in pNL4-3 was replaced with the corresponding region in pNL4-
3.Luc3.R¯E¯. The resulting plasmid was designated as pNL4-3E¯.  
To construct the envelope glycoprotein expression plasmid, the Rev/Env expression 
cassette in pNL4-3 was PCR amplified and subcloned into the vector pcDNA3.1(-) using 
BamHI and XbaI restriction enzymes. The resulting plasmid was designated as 
pcDNA3.1REC.  
To construct the provirus clone that carries mutations in both Vpr and envelope 
glycoproteins, the ORF of Vpr in pNL4-3E¯ was replaced with that of pNL4-3.Luc3.R¯E¯ 
using two restriction enzymes, PflMI and NheI. The resulting plasmid was designated as 
pNL4-3R¯E¯.  
To construct the provirus clone that carries enhanced green fluorescent proteins 
(EGFPs) between matrix and capsid proteins through two linkers that can be cleaved by 
HIV protease during the virion maturation process (27), three DNA fragments were first 
PCR-amplified. Fragment 1 uses pNL4-3 as a template, with forward and reverse primers 
as follows, 5’-GCCAGAGGAGATCTCTCGACG-3’, 5’-
CCATCGTACGCTGGAGGTTCTGCACTATAGGGTAATTTTGG-3’. Fragment 2 uses 
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pEGFP-Vpr as a template, with forward and reverse primers as follows, 5’- 
CTCCAGCGTACGATGGTGAGCAAGGGCGAGGAGC-3’, 5’- 
CTGGCTCGGCCGCTTGTACAGCTCGTCCATGCCGAGAGTG-3’. Fragment 3 uses 
pNL4-3 as a template, with forward and reverse primers as follows, 5’- 
GCGGCCGAGCCAGGTCAGCCAAAATTACCCTATAGTG-3’, 5’- 
CACTTCCCCTTGGTTCTCTCATC-3’. These three DNA fragments were digested by 
BssHII/BsiWI, BsiWI/EagI, or EagI/SphI, respectively, and then sequentially ligated and 
cloned into pNL4-3E¯ using BssHII and SphI restriction sites. The resulting plasmid was 
designated as pNL4-3E¯ MA-EGFP-CA. All of the plasmids constructed above were 
subjected to sequencing to confirm their identity before their use in cell culture and 
transfection procedures. 
 
Production of single-cycle replicative, fluorescently-labeled HIV-1 virions   
HEK 293T/17 cells (ATCC, Manassas, VA) were cultured at 37°C with 5% CO2 in 
DMEM supplemented with 10% FBS (HyClone Laboratories, Logan, UT). Throughout, 
all cell lines were discarded after ten passages and new aliquots of frozen cells were thawed 
to improve reproducibility of virion production and infection experiments. To produce 
single-cycle virions tagged with EGFP, 106 293T cells in a 2-ml culture volume were 
seeded overnight in a 35-mm dish before transfection using the TransIT LT-1 transfection 
reagent (Mirus Bio, Madison, WI). For each dish, 1 µg of the provirus-containing plasmid 
pNL4-3R¯E¯ was used to make the transfection reagent mixture, together with various 
amount of envelope expression plasmid pcDNA3.1REC and pEGFP-Vpr as indicated 
throughout the text. The transfection reagent mixture was incubated at room temperature 
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for 15 min before drop wise addition to the culture media. At designated time points post 
transfection, the culture media together with the transfection reagents was replaced with 
fresh complete media and the incubation was continued at 37°C with 5% CO2. At various 
time points post transfection, the entire culture media containing single-cycle HIV-1 
viruses was collected and filtered through a 0.45-µm syringe filter (Millex-HV PVDF, 
Millipore) in less than 10 minutes on average. The filtrate was then aliquoted on ice, flash-
frozen in either liquid nitrogen or dry ice/ethanol bath and stored in a -80°C freezer. HIV 
virions carrying free EGFPs were generated by transfection of 293T cells with 1 µg pNL4-
3E¯MA-EGFP-CA plasmid and 0.1 µg pcDNA3.1REC in 2-ml volume in a 35-mm dish.  
 
Infection assay in TZM-bl cell line   
TZM-bl cells (cat#8129, NIH AIDS Research and Reference Reagent Program) were 
cultured at 37°C with 5% CO2 in DMEM supplemented with 10% FBS. To determine the 
concentration of infectious HIV-1 particles, Ci.p., 8X104 TZM-bl cells in a 1-ml culture 
volume were seeded in each well of a 12-well plate one day prior to infection. On the next 
day, virus stocks taken out of -80°C freezer were placed in a room temperature water bath 
until just thawed, and serially diluted in complete media containing 20 µg/ml DEAE-
dextran. 100 µl of viruses at each dilution were layered on top of the cell and the infection 
was continued for two hours at 37°C with gentle rocking every 30 min. At the end of two 
hours, 1 ml of complete media was added to each well and the incubation was continued 
at 37°C for 48 hours with 5% CO2. At the end of 48 hours, cells were fixed in 2% 
gluteraldehyde at room temperature for five minutes. After fixation, the cells were washed 
three times with PBS, and stained for 50 min at 37°C using cell staining solution provided 
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in the beta-galactosidase staining kit (Mirus Bio, Madison, WI). After incubation, the cells 
were washed three times with milliQ water and the number of blue cells in each well was 
counted with a Nikon TS100-F inverted microscope.  
 
p24 ELISA Assay   
To determine the concentration of physical particles for each virion preparations, 
Cp.p., we measured p24 values for each virion preparation using p24 ELISA and converted 
p24 values to concentrations of physical particles. The p24 values were measured using 
HIV-1 p24 Antigen Capture Kit (Advanced Bioscience Laboratories, Rockville, MD) 
following the manufacturer’s instructions. Briefly, properly diluted virus samples were 
lysed and captured in a micro-ELISA plate at 37°C for one hour. The wells were then 
washed and the specifically captured p24 antigen was incubated with human anti-p24 
polyclonal antibodies conjugated with peroxidase at 37°C for one hour. At the end of 
incubation, peroxidase substrate was added and the reaction was continued for 30 minutes 
at room temperature. The reaction was stopped by adding 2N Sulfuric acid. The absorbance 
at 450 nm was measured using a SynergyTM HT multi-mode microplate reader. The 
stoichiometry of Gag protein in HIV-1 has been determined to be approximately 2,500 (33, 
34). Using a molecular weight of 24 kD for p24, this yields 107particles per ng of p24. 
Thus one can estimate the number of physical particles based on p24 ELISA measurement 
for each virion preparation. Independently, we also validated this method using confocal 
imaging and direct counting of virion particles. The infectivity of single-cycle HIV-1 was 
calculated by taking the ratio between infectious particle concentration (Ci.p.) and physical 
particle concentration (Cp.p.). 
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Confocal imaging and counting of virions   
HIV Virions carrying EGFP-Vpr or free EGFPs at various dilutions in 200 µl 
complete media (90% DMEM with 10% FBS) were deposited onto a Poly-L-Lysine (PLL) 
-coated coverslip, and incubated at room temperature for 30 minutes (35). The media was 
then removed and virions on the surface were fixed with 4% paraformaldehyde (PFA) for 
10 minutes at room temperature. The coverslip was then washed with PBS and mounted 
onto a glass cover slide with 3 µl mounting media, sealed with nail polish and imaged using 
an Olympus FluoView 500 Laser Scanning Confocal Microscope. The virion particles in a 
fluorescence image were identified and quantitated using a custom-written MATLAB 
script. In this script, the virion particles were identified based on a global threshold 
automatically established by maximizing the inter-class variance between the foreground 
and background (Otsu’s method) (36), which eliminates the use of any subjective 
parameters during image analysis. Several different areas on a single coverslip sample as 
noted in each figure were imaged and the resulting particle numbers in each area were 
averaged and plotted in Figure 2.5A. Each particle size was measured based on the 
identification of virion particles. Sum intensity was defined as the total intensity from each 
pixel in one virion. Mean intensity was defined as a ratio of sum intensity to each particle 
size.  
 
2.4. Results    
2.4.1. Measurement of infectious particle concentration (Ci.p.) for single-cycle viruses 
Throughout this work, we define infectivity as the fraction of virions that can 
establish a productive infection in a host indicator cell line. To establish a quantitative 
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framework for measurement of infectivity, we generated single-cycle virions using NL4-3 
virus and infected TZM-bl cell lines (37) using virions produced under various conditions. 
This cell line has been one of the popular cell lines for HIV-1 infection and thus comparison 
among labs is possible (38-41). Cells were infected for two hours at 37°C and further 
incubated for 48 hours to allow production of β-galactosidase in infected cells. We then 
used X-Gal staining to visualize these infected cells, which appeared in blue color (42). It 
is worth noting that un-integrated provirus DNA can also turn on Tat transcription (43) and 
cells may turn blue in the absence of the provirus integration (44). However, this 
integration-independent infectivity is only 5% of total infectivity observed for NL4-3 virus 
in TZM-bl cells (45). Thus, counting stained cells under a microscope (Figure 2.1A and B) 
measures the number of cells that have been productively infected by NL4-3 virus, i.e., 
provirus has been integrated into cellular chromosomes, which upon transcriptional 
activation, produces Tat protein that subsequently activates the expression of β-
galactosidase.  
In the presence of viral Vpr protein (3, 46-48), majorities of blue cells were singles 
and each blue cell was counted as resulting from one infectious particle under current 
Multiplicity of Infection (MOI) conditions (0.005). Occasionally, blue cells appeared as 
clusters due to cell division and the cluster of blue cells was counted as resulting from one 
infectious particle. This counting method was supported by our observations shown in 
Figure 2.1C, where the number of clustered blue cells was correlated with the progression 
of cell cycle. HIV-1 virions carrying Vpr proteins resulted in less clusters of blue cells due 
to cell cycle arrest by Vpr proteins (3, 46-48). To examine the linearity of this assay, we 
varied the dilution factors for the input virions and the resulting blue cells were counted. A 
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typical result is shown in Figure 2.1D, where the number of blue cells was plotted as a 
function of the dilution factor for each 100 µl of virus. Linear regression of this plot yields 
a straight line with an intercept close to zero (-5.4±2.5) and a slope of (4.30±0.05) 
X106/ml with adjusted R-square of 0.998. Because MOI were less than 1 under these 
conditions (the highest MOI = 0.005), this dependence strongly suggests that a single HIV-
1 virion is capable of establishing an infection, and each blue cell resulted from infection 
by a single virus, with 95% chance of being an integrated provirus. In fact, for even the 
most concentrated virus in these experiments, the total number of viral physical particles 
as determined using p24 ELISA was less than the total number of starting cells. Thus, the 
slope in Figure 2.1D directly measures the concentration of infectious particles, Ci.p.. 
Based on the strong linear correlation, we have used blue-cell counting to determine Ci.p. 
in TZM-bl cells throughout, and compare them for virions produced under various 
conditions. 
 
2.4.2. Infectivity improvement of EGFP-Vpr HIV-1 virions 
Inhibitory effect of EGFP tagging on virion infectivity 
The infectivity for both EGFP-tagged virions, HIV-1 carrying EGFP-Vpr or free 
EGFPs, is lower than those untagged viruses (21), likely due to the inhibitory effect of 
EGFP tagging on HIV-1 virion infectivity. This effect of inhibition is clear from Figure 
2.2C, where we varied the input pEGFP-Vpr plasmid systematically and measured the 
infectivity of resulting virions. A similar trend of inhibition was also observed for free 
EGFP virions, where an increasing fraction of EGFP-tagged mutant provirus decreases 
virion infectivity (21). There is a trade-off effect between infectivity and fluorescent 
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intensity, thus the optimized infectivity with low fluorescent intensity may be challenging 
to observe fluorescent virions. We then decided to measure fluorescent intensities with 
different inputs of EGFP-Vpr and the result will be discussed in chapter 2.4.4. 
 
Harvest time dependence of virion infectivity   
Recent studies on replicative HIV-1 virions revealed that virions harvested at early 
times from culture media have higher infectivity (12). To explore this phenomenon for 
single-cycle HIV virions, we produced virions carrying EGFP-Vpr and collected HIV-1 
virions at different times post transfection. As revealed in earlier study, infectious particles 
can be detected as early as six hours post transfection (21), reaching a peak value around 
24 hours and the Ci.p. starts to be at a plateau (Figure 2.3A). In contrast, the concentration 
of physical particles Cp.p. continues to increase until 72 hours (Figure 2.3B). As a result, 
the infectivity of virions collected at different times shows a pronounced dependence on 
harvest time, reaching a maximum at 24 hours and dropping off thereafter (Figure 2.3C). 
The difference in infectivity can be as large as fourfold for virions collected at different 
time points post transfection. This time dependence has interesting implications for the 
production of HIV-1 virions by 293T cells; either the virions produced at early times lose 
infectivity with time, or more defective virions are produced at later times after transfection. 
The infectivity decay of HIV-1 virions has been reported previously (7), which is 
attributable to loss of reverse transcriptase activity, biophysical instability of virion 
particles and possibly gp120 shedding, although the shedding of gp120 was later shown to 
be insignificant for NL4-3 virus (49). It was revealed that the infectivity decay is not solely 
due to spontaneous inactivation of these virions in culture media, but rather, production of 
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defective or less infectious virions occurs at the same time so that the overall rate of 
infectivity decay speeds up (21). 
 
Media change post transfection increases HIV-1 infectivity 
The transfection reagent we used, TransIT-LT1, is a low toxicity reagent that is 
comprised of a lipid and protein/polyamine mixture. Although media change is not required 
after transfection using this reagent, we decided to replace the media to test if infectivity 
of HIV-1 virions changes. As shown in Figure 2.3C, media change has a positive impact 
on virion infectivity. The infectivity of EGFP-Vpr virions at early harvest times is higher 
than later ones, similar to the untagged virus (21). Notably, the infectivity of virions 
generated with media change six hours post transfection (open circles) is three or fourfold 
higher than those without (filled squares). This increase in infectivity is due to a slight 
increase in Ci.p. and a concomitant decrease in Cp.p., as shown in Figure 2.3A and B. 
These results confirm that media change after transfection increases HIV-1 virion 
infectivity. 
 
Dependence of HIV infectivity on envelope plasmid input 
Viral envelope glycoproteins are necessary for virus to productive infect cells (50, 
51). Recent studies claims that the low number of envelope spikes on HIV-1 compared to 
other viruses might be the one of reasons for the inefficient transmission of HIV. (17, 24, 
52-54). Based on these observations, a constant mutant provirus DNA (1 µg) was used 
throughout but the envelope plasmid was varied from 0.1 to 4 µg. Thus, the molar ratio 
between the two plasmids, provirus and envelope, varied over two orders of magnitude. 
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Virions were collected at 24 hours post transfection with media change at six hours post 
transfection. Notably, the infectivity of HIV virions changes with increasing envelope 
plasmid and shows a plateau at 1 µg envelope plasmid.  
However, we have used DEAE-dextran for facilitating virus binding to cells for all 
infection assays, which may pose a possibility that the increase in infectivity with more 
input of envelop plasmid is not due solely to higher expression of envelope glycoprotein. 
DEAE-dextran may increase viral infectivity although the expression of envelope 
glycoprotein reaches to a plateau. The infectivity of HIV-1 virions prepared from varied 
inputs of pEnv was assayed as described previously (21) but in the absence of DEAE-
dextran. The infectivity increases with increasing pEnv and shows a peak at 2 μg pEnv 
(Figure 2.4D). The subsequent decrease in virion infectivity may be due to incorporation 
of gp160 at high pEnv (21), which inhibits productive infection of virions (55, 56). Figure 
2.4E shows the fold enhancement of HIV-1 virion infectivity as a function of pEnv due to 
the inclusion of 20 μg/ml DEAE-dextran in the infectivity assay. The fold enhancement 
was calculated as the ratio of virion infectivities measured in the presence and absence of 
DEAE-dextran for the same batch of virions. Thus, the infectivity of HIV virions changes 
with increasing envelope plasmid. 
 
2.4.3. Measurement of physical particle concentration for single-cycle viruses 
The stoichiometry of Gag protein in HIV-1 has been determined to be approximately 
2,500 per virion (33, 34). Using a molecular weight of 24 kD for p24, this yields 107 
particles per ng of p24. One can thus estimate the number of physical particles based on 
p24 ELISA measurement. To support this approach for measurement of Cp.p., the 
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concentration of physical particles, we have developed a confocal imaging and quantitation 
procedure to count the number of virions and examine its correlation with p24 values. This 
procedure uses virions labeled with EGFP fused to Vpr, which allows direct visualization 
of virions encapsulating EGFP-Vpr under a confocal fluorescence microscope (Figure 
2.5A). To objectively quantitate the number of virions in a field of view (FOV), we 
developed a custom-written MATLAB script, which could identify fluorescent particles 
automatically and also output fluorescence intensity associated with each particle for 
statistical purposes. To examine the correlation between the number of particles and p24 
measurement, EGFP-Vpr virions with various p24 values were deposited onto PLL-coated 
coverslips and the resulting particle numbers in a FOV were measured as described in 
Experimental Procedures. Figure 2.5B plots one such result, where the number of 
fluorescent particles identified in a FOV is linearly correlated with their p24 values, with 
adjusted R-square of 0.992 and intercept on y-axis close to zero. Although this imaging 
method cannot provide a direct conversion between the number of virion particles and p24 
values due to the potential presence of virions without EGFP, this correlation supports p24 
values as a measurement of viral Cp.p.. 
 
2.4.4. Distributions of virion size and intensity profile  
By converting an original fluorescent confocal image to a binary image based on 
Otsu’s method (36), the size in pixels of each virion can be identified. As shown in Figure 
2.6A, the distributions of particle size were skewed with all five different virus 
concentrations from 20 to 100 ng/ml based on p24 values. The majority of particle was 1 
or 2 size in pixels, resulting in 1.81 or 2.00 as center values with Gaussian fitting (Figure 
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2.6A). Based on this observation, particle which are 1 and 2 pixels may be background 
since the distribution of them was very different compared to that of rest of particles. 
Therefore, we reanalyzed the data with removing 1 and 2 pixels and fitted Gaussian (Figure 
2.6B). The center values were from 7.16 to 8.18 and the average particle sizes with 
Gaussian fitting were similar with different dilutions of virus, probably implying the 
majority of particles imaged was a single virion.  
With identified virus particles, we further conducted virion intensity mapping by 
varying pEGFP-Vpr amount from 0.05 to 1 µg/ml. The apparent intensity peak increases 
with more input of EGFP-Vpr plasmid regardless of the assumption that 1 and 2 pixels are 
background. Thus, there is a trade-off effect between fluorescent intensity and infectivity 
based on our previous observation of the highest infectivity with 0.3 µg EGFP-Vpr input, 
which concentration is 0.15 µg/ml. However, the distributions of intensity, both mean and 
sum intensities, showed pretty broad (Figure 2.7), meaning virions in culture media were 
heterogeneous in terms of fluorescent intensity, which was also revealed in our recent work 
(26). Thus, we were able to pick 0.15 µg/ml of EGFP-Vpr plasmid input which results in 
the highest infectivity and reasonable intensity profiles amid the broad distribution of 
intensities for further studies.  
 
2.4.5. Labeling efficiency of EGFP-Vpr 
Although EGFP-Vpr fusion protein allows direct visualization of virions 
encapsulating EGFP-Vpr and the number of virion particles and p24 values were strongly 
correlated (Figure 2.5B), the potential presence of virions without EGFP may significantly 
complicate the study of investigating viral entry by imaging them. We compared the 
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number of HIV-1 carrying EGFP-Vpr and free EGFPs under the same p24 conditions. In 
this experiment, we produced HIV-1 carrying free EGFPs by transfecting 293T cells with 
pNL4-3E¯MA-EGFP-CA and pc.DNA3.1REC, resulting in all virus particles identified by 
p24 ELISA should carry EGFPs. With five different p24 values from 33.3 to 100 ng/ml, 
about 50% HIV-1 virions have EGPF-Vpr fusion proteins (Figure 2.8). It means the rest of 
virions without EGFP signal cannot be observed with an approach using fluorescence even 
though they can still infect cells.  
 
2.5. Discussion  
The goal of this study was to characterize HIV-1 carrying EGFP-Vpr in terms of 
infectivity, fluorescent intensity, and labeling efficiency. The apparent low infectivity of 
cell-free HIV virions in culture media has not been fully understood. Whether this is due 
to virions themselves having intrinsically low infectivity or because of viral-cell 
interactions that limit HIV-1 infection remains to be elucidated. The assumption behind 
intrinsic low infectivity for these virions is that a large proportion of virion particles are 
defective, the fraction of which may change in the viral life cycle. The overall infectivity 
of fluorescently-tagged HIV-1 virions can be improved through variation in culture 
conditions, suggesting that these conditions work by reducing defective or less infectious 
virions (Figure 2.2, 2.3, and 2.4). Nevertheless, these improvements are not as dramatic as 
the impact of host cells on HIV-1 infectivity (21). These results indicate that host cells may 
cause a major barrier for HIV-1 infectivity even though the intrinsic infectivity of HIV-1 
virions can be optimized. Also, the viral-cell interactions likely restrict the infectivity of 
HIV-1 virions. For all these events, the single-cycle HIV-1 virions are ideal materials to 
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further address these questions because the single replication cycle allows to dissect 
individual steps in the viral life cycle and their contribution to the overall infectivity of the 
virion. For instance, the impact of early events in virus life cycle on infection, such as the 
kinetics of virion attachment or internalization can be measured and quantitated, which will 
be further discussed in chapter 3. HIV virions with optimized infectivity can be used in 
these mechanistic studies to understand the molecular mechanisms of the apparent low 
infectivity. 
With our transfection system, which used two or three plasmid for producing virions, 
there is a possibility that not all plasmids can transfect each cell. This may contribute to 
the heterogeneity of HIV-1 in virus pool, resulting in the potential presence of virions 
without EGFP. Although our imaging method cannot provide a direct conversion between 
the number of virion particles and p24 values due to the potential presence of virions 
without EGFP, the strong correlation supports p24 values as a measurement of viral Cp.p.. 
Furthermore, we were able to choose 0.15 µg/ml EGFP-Vpr which results in the highest 
infectivity and reasonable intensity profiles amid the broad distribution of intensities for 
further studies even though there is a trade-off effect between fluorescent intensity and 
infectivity.  
Taken together, molecularly cloned HIV-1 that is capable of only a single round of 
infection (1, 2) offers a unique tool to address important questions related to the early event 
of viral infection. In this study, we established how to measure the concentration of 
infectious particles (Ci.p.) for measuring infectivity (Figure 2.1) by taking an advantage of 
Vpr function suppressing G2 cell cycle (3). The infectivity was then optimized by varying 
several virus culture conditions, such as, EGFP-Vpr plasmid input (Figure 2.2), virion 
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harvest time (Figure 2.3), media replacement after transfection (Figure 2.3), and envelope 
plasmid input (Figure 2.4). Also, fluorescent-tagged virion using EGFP-Vpr fusion protein, 
which showed ~50% labeling efficiency (Figure 2.8), allows direct visualization of HIV-1 
encapsulating EGFP-Vpr based on the strong correlation between the number of virion 
particles and the concentration of physical particles (Cp.p.) (Figure 2.5B). Furthermore, we 
were able to pick 0.15 µg/ml of EGFP-Vpr plasmid input which results in the highest 
infectivity (Figure 2.2C) and reasonable intensity profiles amid the broad distribution of 
intensities (Figure 2.7) for further imaging studies although there was a trade-off effect 
between fluorescent intensity and infectivity.  
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2.7 Figures 
 
 
 
 
Figure 2.1. Measurement of infectious HIV-1 virions by blue-cell counting in TZM-bl 
cells.  
 
(A) and (B), representative images of blue TZM-bl cells in 12-well plates for quantitation 
of infectious particles showing well-resolved single cells and clusters of cells such as 
doublets. (C) Fraction of single or clustered blue cells depends on the presence of Vpr in 
single-cycle HIV-1 virions. Vpr+ virions were generated from transfection of 293T cells 
with 1 µg pNL4-3E¯ and 0.1 µg pcDNA3.1REC. Vpr¯ virions were generated from 
transfection of 293T cells with 1 mg pNL4-3R¯ E¯ and 0.1 µg pcDNA3.1REC. Both 
virions were harvested 48 hours post transfection without media change. TZM-bl cells were 
infected by either of these two virions and the resulting single or clustered blue cells were 
counted. Error bars are standard deviations from six independent replicates of the same 
experiments. (D) The number of blue cells was plotted as a function of virion dilution factor 
per 100 µl of virus. The red line shows its linear regression. The virus was produced by 
transfection of 293T cells using 1.0 µg pNL4-3E¯ plasmid and 0.2 µg pcDNA3.1REC, 
followed by collection 48 hours post transfection without media change. Error bars are 
standard deviations from six independent replicates of the same experiments. 
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Figure 2.2. Infectivity of EGFP-tagged single-cycle virions as a function of input 
EGFP.  
 
Panels (A), (B) and (C) show Ci.p., Cp.p., and infectivity of HIV-1 virions tagged with 
EGFP-Vpr, as a function of input pEGFP-Vpr plasmid. The viruses were collected 48 hours 
post transfection without media change. Error bars are standard deviations from three 
independent replicates of the same experiments. 
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Figure 2.3. Ci.p., Cp.p., and infectivity of HIV-1 virions as a function of harvest time 
post transfection and media change at 6h PT.  
 
Panels (A), (B) and (C) show Ci.p., Cp.p., and infectivity of HIV-1 virions tagged with 
EGFP-Vpr, as a function of harvest time post transfection, with media change six hours 
post transfection (open circles) and without (filled squares). Virions were produced using 
1.0 µg pNL4-3R¯E¯ plasmid, 0.3 µg pEGFp-Vpr and 0.1 µg pcDNA3.1REC. Error bars 
are standard deviations from three independent replicates of the same experiments. 
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Figure 2.4. Dependence of HIV-1 virion infectivity on envelope plasmid input during 
transfection. 
 
(A), (B) and (C) show Ci.p., Cp.p. and infectivity for HIV-1 virions tagged with EGFP-
Vpr produced with various inputs of envelope plasmid pcDNA3.1REC. The viruses were 
collected 24 hours post transfection with media change at 6h post transfection. Ci.p. was 
zero with no envelope. Error bars are standard deviations from three independent replicates 
of the same experiments. (D) Infectivity of HIV-1 virions as a function of pEnv in the 
absence of DEAE-dextran and the quantitative effect of DEAE-dextran in enhancing HIV-
1 infectivity. The error bars are standard deviations from three independent repeats of the 
same experiments for 0.005, 0.01, 0.05, 0.1, 2, 4 μg pEnv, and from two independent 
repeats of the same experiments for 0.2 and 1 μg pEnv due to the shortage of virus stocks. 
(E) Fold enhancement of HIV-1 virion infectivity as a function of pEnv due to the inclusion 
of 20 μg/ml DEAE-dextran in the infectivity assay. The fold enhancement was calculated 
as the ratio of virion infectivities measured in the presence and absence of DEAE-dextran 
for the same batch of virions.  
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Figure 2.5. Confocal imaging of EGFP-Vpr virions and particle quantitation.  
 
(A) A schematic figure showing how to deposit and image virions on PLL-coated coverslip. 
With custom-written MATLAB, an original confocal image was converted into a binary 
image for identifying each virion. With identified virions, the intensity can be measured 
with an original image. The image is 1024 by 1024 pixels with a physical size of 124 by 
122 nm in x and y dimensions. (B) The correlation between numbers of fluorescent 
particles identified from a FOV and the input p24 values measured using ELISA. The linear 
regression is shown in red line. HIV-1 virions tagged with EGFP-Vpr was produced by 
transfecting 293T cells with 1 µg pNL4-3R¯E¯, 0.1 µg pcDNA3.1REC, and 0.3 µg 
pEGFP-Vpr. The viruses were collected 24 hours post transfection with media change at 
6h post transfection. Error bars for each sample are standard deviations from at least nine 
different areas analyzed on a coverslip surface. 
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Figure 2.6. Size distribution of EGFP-Vpr virion. 
 
(A) Size distribution of all fluorescent particles identified by custom-written MATLAB 
with five different Cp.p. values. (B) Size distribution of fluorescent particle except 1 and 2 
pixels identified by custom-written MATLAB with five different Cp.p. values. The table 
shows center and standard error values from each Gaussian fitting. HIV-1 virions tagged 
with EGFP-Vpr was produced by transfecting 293T cells with 1 µg pNL4-3R¯E¯, 0.1 µg 
pcDNA3.1REC, and 0.3 µg pEGFP-Vpr. The viruses were collected 24 hours post 
transfection with media change at 6h post transfection. Error bars for each sample are 
standard deviations from five different areas analyzed on a coverslip surface. 
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Figure 2.7. Intensity distribution of EGFP-Vpr virions with different inputs of EGFP-
Vpr.  
 
(A) Mean intensity distribution of all EGFP-Vpr virions identified and measured by 
MATLAB used in Figure 2.2. (B) Mean intensity distribution of EGFP-Vpr virions 
excluding 1 and 2 pixels. (C) Sum intensity distribution of all EGFP-Vpr virions. (D) Sum 
intensity distribution of EGFP-Vpr virions excluding 1 and 2 pixels. Mean intensity can be 
calculated as the ratio of sum intensity to particle size. Sum intensity of each virion was 
defined as the total intensity of each virion. HIV-1 virions tagged with EGFP-Vpr produced 
with various inputs of pEGFP-Vpr from 0.05 to 1 µg/ml. The viruses were collected 24 
hours post transfection with media change at 6h post transfection. Error bars for each 
sample are standard deviations from ten different areas analyzed on a coverslip surface. 
 
 
 
 
 
 
 
 
59 
 
 
Figure 2.8. Labeling efficiency of HIV-1 tagged with EGFP-Vpr.   
 
(A) The correlation between numbers of fluorescent particles identified in a FOV and the 
input p24 values measured using ELISA. The linear regression is shown in red line. All 
adjusted R square values are above 0.99. (B) The slope shows the labeling efficiency of 
EGFP-Vpr HIV-1 virions. HIV-1 virions tagged with EGFP-Vpr was produced by 
transfecting 293T cells with 1 µg pNL4-3R¯E¯, 0.1 µg pcDNA3.1REC, and 0.3 µg 
pEGFP-Vpr. HIV-1 virion carrying free EGFPs was produced with 1 µg pNL4-3E¯MA-
EGFP-CA 0.1 µg pcDNA3.1REC. The viruses were collected 24 hours (EGFP-Vpr) or 18 
hours (free EGFPs) post transfection with media change at 6h post transfection. Error bars 
for each sample are standard deviations from at least ten different areas analyzed on a 
coverslip surface except the lowest p24 values from three areas. 
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Chapter 3. 
 
Determine Entry Pathways that Lead to Productive 
HIV-1 Infection 
 
3.1. Abstract 
Although it has been well established that HIV initiates a T cell infection by binding 
to CD4 and chemokine coreceptors on the cell surface, the fundamental mechanisms of 
receptor-mediated viral entry for a productive infection have not been completely 
understood. In this chapter, we determined to investigate entry pathways that lead to 
productive HIV-1 infection with the characterized and optimized fluorescently-labeled, 
single-cycle replicative HIV-1 in chapter 2. Possible scenarios for productive viral entry 
are direct fusion at the plasma membrane, endocytosis, or both.  Although direct fusion has 
been long thought to be the pathway for HIV-1 entry, this notion has been challenged 
recently by various studies (1,2).  This question is fundamentally important for molecular 
understanding of HIV-1 infection. To determine if virion endocytosis can lead to 
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productive infection, we seek to correlate the inhibition of endocytosis and inhibition of 
infection. First of all, we can clearly visualize HIV-1 virions colocalized in early 
endosomes, and the fraction of colocalization is similar between HIV-1 and VSV-G 
pseudotyped virions. Also, we used various inhibitors that are known to block various steps 
of endocytosis. The results from three different cell lines suggest that endocytosis can 
indeed lead to productive infection, as revealed by the specific inhibition of HIV-1 
infectivity by the dynamin I K44A mutant. However, endocytosis may not be the only 
productive pathway for HIV-1 infection because all these inhibition data that we have 
observed appear to be partial, which is in sharp contrast to inhibition by T20. These results 
also suggest that endocytosed virions need to fuse with endosomal membrane for 
productive infection. Understanding of productive HIV-1 entry will help elucidate viral 
pathogenesis and further develop therapeutics that is aimed to block HIV entry to CD4+ T 
cells.  
 
3.2. Introduction 
Endocytosis is an required entry step for enveloped viruses whose fusion proteins 
are activated by acidic pH (3). In contrast, viruses that undergo fusion upon interacting 
with corresponding cellular receptors regardless of the pH have been believed to fuse 
directly with cellular plasma membrane. Consistently, it was revealed that HIV-1 entry and 
viral membrane fusion do not require exposure to low pH (4). Productive entry of HIV-1 
into CD4+ T cells is initiated by binding of the viral envelope gp120 to CD4 receptor. This 
binding causes a cascade of conformational changes in both the gp120 and gp41 that 
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eventually lead to virus-cell membrane fusion and HIV-1 entry (5,6). Subsequently, 
transcription of the viral RNA by the viral reverse transcriptase generates a double-stranded 
DNA copy of the viral genome, which is transported to the nucleus and integrated into host 
chromosomes to establish a successful infection (7). Studies over the years have uncovered 
many important aspects of HIV entry into CD4+ T cells and mechanisms of subsequent 
killing (8,9). Although inhibitors targeting viral entry have become the new generation of 
antiretroviral drugs, our understanding on the molecular basis of HIV entry has not been 
completely understood. Thus, it is critical to elucidate the mechanisms by which HIV enters 
CD4+ T cells. Such knowledge will not only enlighten our understanding of HIV 
pathogenesis, but also help develop therapeutics that is aimed to block HIV entry to CD4+ 
T cells.  
Early studies of HIV-1 entry have focused on the identification of receptors on T cell 
surface mediating viral productive entry. These have revealed that CD4 and chemokine 
coreceptors (CCR5 or CXCR4) are necessary for HIV entry to CD4+ T cells (10). Although 
it has not been observed directly, HIV-1 entry is long thought to be a direct fusion between 
viral membrane and T cell membrane (3,6,11). There are several studies supporting this 
mechanism: first of all, interaction between CD4 and envelope protein gp120 can trigger 
conformational changes to fusion-active structure (6); second, cell-cell fusion can be 
mediated by HIV envelope proteins expressed on one cell surface and receptors (12); third, 
viral entry does not require the endocytosis of its receptor CD4 nor does it depend on low 
pH, which may be necessary for viral endocytosis (13,14); finally, electron microscopy 
(EM) images have shown the intermediates of a direct fusion between virus and cell 
membrane (15-17).  
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However, a recent study using real time fluorescence imaging technology at single 
molecule level has directly shown that HIV-1 enter its target cells via dynamin-dependent 
endocytosis instead of direct fusion in TZM-bl cells (1). Consistently, viral fusion with 
endosomes and micropinosomes has been observed by EM (18,19). Second, viral infection 
increases with blocking the acidification of endosomal compartments and apparently by 
sparing the virus from degradation in lysosomes (20-22). Third, efficient infection by VSV-
G pseudotyped virus (23) shows that there are no significant limitations associated with 
viral endocytosis. Lastly, the inhibition of clathrin-mediated endocytosis decreases the 
efficacy of virus-cell fusion and infection in HeLa-derived cells (24).  
Dynamin is distinguished from regulatory GTPases by its low affinity for GTP and 
high turnover rate of GTP hydrolysis (25,26). It is necessary for clathrin-dependent coated 
vesicle formation during the process of vesicles pinching off from a plasma membrane (27). 
Dynamin is organized into multiple domains. The N-terminal GTPase domain is 
structurally related to other GTPases (28), and mutations impairing GTP binding and/or 
hydrolysis block endocytosis (29,30).  
Thus, for more specific inhibition on dynamin-dependent endocytosis, we used 
dynamin I K44A mutant (31), which acts as a dominant-negative fashion to block the 
formation of functional dynamin oligomers required for dynamin-dependent endocytosis 
(32-34). Also, to determine if virion endocytosis can lead to productive infection, various 
inhibitors that are known to block various steps of endocytosis were used. These studies 
were compared with VSV-G pseudotyped virions, which are known to enter cells through 
receptor-dependent endocytosis (35). Furthermore, one can postulate that viral entry might 
be different among cell lines since protein compositions on cellular surface and cellular 
68 
 
components in cytosol are different. CD4+ T lymphocyte is naturally targeted by HIV-1 
(10). Thus, several T cell lines, such as SupT1, Rev-CEM or Jurkat cells, were also used. 
However, endocytosis may not be the only productive pathway for HIV-1 infection. Either 
entry mechanism, direct fusion on plasma membrane or endocytosis, membrane fusion 
between viral and cellular membranes is required for virus to productively infect host cells 
(6). Thus, T20, which displayed outstanding effects of fusion inhibition (36,37), was used 
as a positive control for inhibition on viral infection. T20, the first clinically approved 
fusion inhibitor by FDA, is 36 amino acid synthetic peptide which is homologous to some 
parts of C terminal heptad repeat (CHR) and tryptophan-rich regions of gp41-encoded 
fusion machinery (38).   
Possible scenarios for productive viral entry are direct fusion at cellular plasma 
membrane, endocytosis, or both.  Although direct fusion is thought to be the pathway for 
HIV-1 entry (3,5,11), this has been challenged recently by various studies (1,2).  This 
question is fundamentally important for molecular understanding of HIV-1 infection. In 
this study, in order to determine if virion endocytosis can lead to productive infection, we 
seek to correlate the inhibition of endocytosis and inhibition of infection.  
 
3.3. Materials and Methods 
Virus production 
HEK 293T/17 cells (AYCC, Manassas, VA) were cultured at 37°C with 5% of CO2 
in media including 90% of DMEM and 10% of FBS (HyClone, Laboratories, Logan, UT). 
All cells for virus production were less than five times passaged. To produce single-cycle 
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HIV-1 virions, 106 293T cells in 2-ml were seeded, settled overnight in 6-well plate and 
transfected with necessary plasmids using TransIT LT-1 transfection reagent (Mirus Bio, 
Madison, WI). For each well, 1 µg of proviral DNA as pNL4-3R¯E¯ was used together 
with various amount of envelope expression plasmid, pcDNA3.1REC and 0.3 µg of 
pEGFP-Vpr. HIV-1 virions carrying 50% free EGFPs or mCherrys were produced with 0.5 
µg of pNL4-3E¯ and 0.5 µg of pNL4-3E¯MA-EGFP-CA or pNL4-3E¯MA-mCherry-CA 
plasmids with 0.1 µg of pcDNA3.1REC. The amount of plasmids for EGFP tags was 
determined based on our previous work in chapter 2 (39). The entire culture media 
including virus was replaced at 6 hours post transfection, collected and filtered using a 
0.45-µm syringe filter (Millex-HV PVDF, Millipore) at 24 post transfection for EGFP-Vpr. 
For free EGFP tags, 18 hours was used as a harvesting time. All virus samples were flash 
frozen and stored -80°C. All detailed transfection and virus preparation procedures 
followed the protocol described earlier in our work (39). 
NL4-3 is an HIV-1 strain widely used for production of cloned HIV-1 virions (40-
42), which was used for all our studies otherwise we noted. HXB2 strain (pIIIenv 3-1, cat 
289, NIH AIDS Research and Reference Reagent Program) was used as envelope 
glycoprotein (43) only in Figure 3.10B,.  
 
Construction of plasmids  
The construction procedures of all plasmids except HXB2 envelope expression 
plasmid were described in chapter 2. To construct HXB2 envelope glycoprotein expression 
plasmid, the Rev/Env expression cassette in pIIIenv 3-1 was PCR amplified and subcloned 
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into the vector pcDNA3.1(-) using NotI and EcoRI restriction enzymes. The resulting 
plasmid was designated as pcDNA3.1REC/HXB2. pIIIenv 3-1 was used as a template, with 
forward and reverse primers as follows, 5’-NotI 
CACAGCGGCCGCGCCTTAGGCATCTCCTAT-3’, 5’-EcoRI 
CACAGAATTCTAGCCCTTCCAGTCCCCCCTTTTCTTTTA-3’. 
 
Preparation of dynasore, chlorpromazine, and T20 
Dynasore (Sigma-Aldrich) was solubilized in DMSO, and chlorpromazine (Sigma-
Aldrich) and T20 (Roche) were prepared in distilled water. All inhibitors were flash-frozen, 
aliquoted, and stored in -80°C freezer. 
 
Optimization of DEAE-dextran concentration in each cell line 
Productive infections with different concentrations of DEAE-dextran were 
quantitated by following each infection assay in TZM-bl and T cell lines, such as SupT1 
or Jurkat cells. For Rev-CEM cells, 5 µg/ml was chosen in our previous work (39). Each 
concentration of DEAE-dextran was optimized based on the highest infectious virus 
concentration in each cell line. With all concentrations of DEAE-dextran, the fractions of 
live cells in terms of cellular permeability by trypan blue assay (44,45) were above 95% 
except 20 µg/ml with Jurkat cells, whose fraction was 73% (data not shown), resulting in 
picking up 10 µg/ml instead of 20 µg/ml. 
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Imaging and quantitating the localization of HIV-1 and VSV-G pseudotyped virion 
inside early endosomes 
105 TZM-bl cells (cat#8129, NIH AIDS Research and Reference Reagent Program) 
were seeded on PLL-coated coverslip and incubated overnight at 37°C with 5% CO2. Cells 
were inoculated with 2 ng (MOP 200) HIV-1 carrying free EGFPs for 15, 30 minutes or 2 
hours with every 15 minutes rocking at 37°C with 5% CO2. Virus inoculation included 20 
µg/ml of DEAE-dextran, which has optimized infectivity in TZM-bl cell line. Complete 
media including free virions was removed. Cells on coverslip were washed with PBS three 
times, fixed with 4% paraformaldehyde for 10 minutes at room temperature, and washed 
with TBS. Cells were then permeabilized with 0.1% Triton X-100/TBS for 30 minutes at 
room temperature, and washed twice with TBS. For preventing nonspecific binding of 
antibodies, SuperBlock blocking buffer (Pierce Biotech) was incubated with samples for 
30 minutes at room temperature. 1 µg/ml Rabbit polyclonal antibody to EEA1 (Invitrogen) 
was prepared using 90% TBS/10% SuperBlock and incubated with samples for 1 hours at 
room temperature. To remove unbound primary antibodies, cells were washed with 90% 
TBS/10% SuperBlock three times. 4 µg/ml Goat polyclonal secondary antibody to Rabbit 
IgG labeled with Alexa 594 (Invitrogen) was incubated and washed with the same 
condition as primary antibody. The coverslip was mounted on a glass cover slide with 
mounting media, sealed with nail polish, and imaged using an Olympus FluoView 500 
Laser Scanning Confocal Microscope. Confocal images were collected with Argon and 
HeNe Red lasers using 100X objectives and 250 nm step size. Custom-written MATLAB 
was able to solve the issue that there were fluorescent viral particles present on several 
stacks of confocal images when quantitating the total number of virions in a FOV. Each 
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fluorescent virion was identified by recognizing all overlapping virion region based on 
centroid-to-centroid distances, globally finding the shortest distances, and correlating and 
relabeling particle regions. The number of colocalized virus particles showing yellow color 
was manually picked. The fraction of colocalization was from more than 5 areas up to 10 
of confocal images.  
 
Toxicity of inhibitors in terms of cellular membrane permeability and growth  
TZM-bl, Rev-CEM, or SupT1 cells were pretreated with dynasore or chlorpromazine 
for 30 minutes at 37°C, and further incubated for 2 or 5 days, following the infection assay 
without virus infection. Cells were then collected and incubated with 0.4% w/v trypan blue 
dye for 5 minutes at room temperature and measured the fraction of non-permeabilized 
cells following the previous protocol (44,45). Heat-killed cells in 80°C for 10 minutes as a 
positive control showed more than 99% permeabilized cells showing blue colors in a 
microscope. T20 didn’t show any apparent toxicity within the range of concentrations used 
for all cell lines, however, high concentrations of dynasore or chlorpromazine showed a 
toxicity. Based on our observation, we were able to use up to 200, 175, or 75 µM dynasore 
for TZM-bl, Rev-CEM, or SupT1, respectively for our further inhibition assays.  
 
Measuring the inhibition on productive infection in TZM-bl cell line 
For measuring inhibition on infections by dyn I K44A, we transfected TZM-bl cells 
for 24 hours with 1, 2, or 5 µg of each plasmid, pcDNA3.1(-), wild-type HA-dyn I, non-
tagged dyn I K44A from rat, or HA-tagged dyn I K44A from human. We used TransIT LT-
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1 as a transfection reagent (Mirus Bio, Madison, WI). Then, cells were trypsinized and 
8x104  cells in 1-ml were seeded in 12-well plate and settled at 37°C. After 6 hours, 
complete media was removed and cells were inoculated with 100 µl of diluted single-cycle 
HIV-1. Inoculation was done at 37°C for 2 hours with every 15 minutes rocking in the 
presence of 20 µg/ml DEAE-dextran. Cells were further incubated for 2 days at 37°C by 
adding 1-ml of complete media. Cells were then fixed with 2% gluteraldehyde for 5 
minutes at room temperature, and stained using β-galactosidase staining kit (Mirus Bio, 
Madison, WI) for 50 minutes at 37°C. The number of blue cells were counted with a 
microscope. The inhibition data was calculated by normalizing the number of blue cells in 
each well with TZM-bl cells, which had transfected with pcDNA3.1(-). 
In order to quantitate the inhibitory effect of several inhibitors on viral infection, 
8x104 cells in 1-ml were seeded in 12-well plate and incubated at 37°C. Complete media 
was removed and 100 µl of complete media containing each concentration of dynasore was 
pretreated with TZM-bl cells for 30 minutes at 37°C. With non-toxic concentration of 
dynasore in terms of membrane permeability and cell growth, we was able to use up to 200 
µM dynasore in TZM-bl cells. Cells were then inoculated with 100 µl of free mCherry-
labeled virus containing dynasore for reaching the same concentration during pretreatment 
step. There was no apparent difference in viral infection between the presence and absence 
of dynasore during inoculation (data not shown). In the case of T20, which acts on virus, 
cells were inoculated with a mixture of virus and certain concentration of T20 instead of 
pretreatment. Inoculation was done at 37°C for 2 hours with every 15 minutes rocking in 
the presence of 20 µg/ml DEAE-dextran. Inoculum was removed and cells were washed 
once with complete media. Cells were further incubated for 2 days at 37°C by adding 1-ml 
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of complete media. All further infection assay was the same as the above experiment. The 
inhibition data was calculated by normalizing the number of blue cells in each well with 
TZM-bl cells, which had not been pretreated with dynasore.  
 
Measuring the transfection efficiency in TZM-bl cell line 
106 TZM-bl cells in 2-ml were transfected with 2 µg of pcDNA 3.1(-), dyn I-EGFP, 
or dyn I K44A-EGFP by using 2 µl of TransIT LT-1 to 1 µg DNA. They were harvested for 
24 hours, trypsinized, and washed with complete media. Cells were then fixed with 4% 
paraformaldehyde at room temperature for 10 minutes and washed with PBS. They were 
analyzed with a flow cytometer (FACS Canto II) using a 488 nm laser.   
 
Measuring the inhibition on productive infection in Rev-CEM, and SupT1 cell lines 
Rev-CEM (cat#11467, NIH AIDS Research and Reference Reagent Program), 
SupT1 (cat#100), or Jurkat cells (cat#177) were cultured at 37°C with 5% of CO2 in 
medium including 90% of RPMI and 10% of FBS. 2X105of each T cell line in 200 µl were 
pretreated with a certain concentration of dynasore for 30 minutes at 37°C. With non-toxic 
concentration of dynasore in terms of membrane permeability and cell growth, we was able 
to use up to 200 µM for Rev-CEM and 75 µM for SupT1 cells. 200 µl of cells were 
inoculated with 100 µl of 50% free mCherry-labeled virus including dynasore for reaching 
the same concentration of dynasore in 300 µl volume of inoculum. There was no apparent 
difference in the inhibition on viral infection between the presence and absence of dynasore 
during inoculation (data not shown). Inoculation was done for 2 hours at 37°C with 
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automatic rocking in the presence of 5 or 10 µg/ml DEAE-dextran for Rev-CEM or SupT1 
cells respectively. Free virions and dynasore were removed by washing with complete 
media. They further incubated for 5 days at 37°C in 2-ml of complete media. Cells were 
fixed with 2% paraformaldehyde for 5 minutes at room temperature and washed with PBS. 
mCherry or EGFP positive cells were quantitated with a flow cytometer (iCyt Synergy, 
Sony). With Rev-CEM cells, infected cells can be quantitated by mCherry or EGFP signal. 
Infected SupT1 cells showed mCherry signals. The fraction of infected cells were counted 
with a flow cytometer using 488 nm and 561 nm lasers.  
 
Measuring the transferrin uptake in TZM-bl 
3X104 TZM-bl cells in 1-ml were seeded in each well with a 12-well plate and 
settled for overnight. They were pretreated with 40, 80, 200 µM of dynasore for 30 minutes 
at 37°C and incubated with 20 µg/ml of Alexa 488 transferrin conjugate (Invitrogen) for 5 
minutes at 37°C followed by at 4°C for 20 minutes. Controls were incubated with the same 
concentration of transferrin conjugates for 25 minutes at 4°C. Transferrin solutions were 
prepared with DMEM without FBS. Then, cells were washed with pre-chilled PBS six 
times and incubated with pre-chilled pH 2.0 buffer for 5 minutes at 4°C followed by pre-
chilled PBS washing twice to remove transferrin bound on cell surface. pH 2.0 buffer was 
made using 500 mM NaCl and 0.2 N glacial acetic acid with distilled water (46). Cells 
were trypsinized, fixed with 4% paraformaldehyde for 10 minutes at room temperature, 
washed with PBS three times, and analyzed with a flow cytometer (FACS Canto II) using 
a 488 nm laser (47). For measuring the effect of dyn I K44A on transferrin uptake, all 
following procedures were the same as previous protocol other than using transfected 
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TZM-bl cells. 
 
3.4. Results   
3.4.1. Colocalization of HIV-1 virion with early endosomes 
In order to start investigating whether HIV-1 can be internalized via receptor-
dependent endocytosis, we visualized both HIV-1 virions carrying free EGFPs and early 
endosomes inside TZM-bl cells. Early endosome antigen 1 (EEA1) is well known to 
exclusively localize in early endosomes (48-50). We can clearly observe yellow spots from 
the colocalization of HIV-1 virions showing green color and EEA1, which was 
immunostained by Alexa 594 (Figure 3.2A). The fraction of colocalization was quantitated 
as a ratio of the number of fluorescent virions colocalized with EEA1 to the total number 
of virions recognized by custom-written MATLAB in all stacks of confocal images in a 
FOV.  
Since endocytosis is a pretty fast event, virus was inoculated with TZM-bl cells for 
from 15 to 30 minutes, which are shorter than 2 hours generally used for checking a 
productive infection (39,51). Around 10% of fluorescent HIV-1 existed inside early 
endosomes with all different inoculation time points (Figure 3.2C). This would be one of 
the evidences that some extent of HIV-1 virions enter target cells via receptor-dependent 
endocytosis and the viral uptake is quite fast, taking less than 15 minutes. Since VSV-G 
has been known to enter cells through receptor-mediated endocytosis (35), we used VSV-
G pseudotyped virions as a positive control. We compared the fraction of colocalization 
inside early endosomes between genuine HIV-1 virions carrying envelope glycoproteins 
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from NL4-3 strain and VSV-G pseudotyped one. Both HIV-1 and VSV-G pseudotyped 
virions were visualized by carrying free EGFPs by inserting EGFP in between MA and CA 
(1). Around 10% of fluorescent particles carrying either genuine viral envelope or VSV-G 
was localized inside early endosomes with all different inoculation time points from 15 
minutes to 2 hours (Figure 3.2C).  
Thus, HIV-1 was clearly present in early endosomes and the fraction of colocalized 
virions between HIV-1 and VSV-G pseudotyped virion was comparable. However, there is 
a possibility that all virions in early endosomes undergo lysosomal degradation. It is also 
feasible some portion of endocytosed virus particles in early endosomes may cause 
productive infection by further membrane fusion between virus and endosome. 
Furthermore, both direct fusion and endocytosis might be able to the way HIV-1 infects its 
target cell. Therefore, our following approache would be investigating the correlation 
between the inhibition of endocytosis and inhibition of productive infection.  
 
3.4.2. Seeking correlation between inhibition of productive HIV-1 infection and 
inhibition of endocytosis 
The above studies showed HIV-1 can be internalized into early endosomes via 
receptor-dependent endocytosis (Figure 3.2A). This is consistent with a recent study 
claiming HIV-1 enter TZM-bl cells via dynamin-dependent endocytosis in TZM-bl cells 
(1). Dynamin is necessary for clathrin-dependent coated vesicle formation during the 
process of vesicles pinching off from cellular plasma membrane (27). To determine if 
virion endocytosis can lead to productive infection, we used various inhibitors that are 
known to block various steps of endocytosis. For more specific inhibition on dynamin-
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dependent endocytosis, we used dyn I K44A mutant (31), which acts as a dominant-
negative fashion to block the formation of functional dynamin oligomers required for 
dynamin-dependent endocytosis (32-34). TZM-bl cell line, which is engineered to express 
CD4 receptors, CXCR4, and CCR coreceptors (52), has been widely used as an indicator 
cell line for measuring HIV-1 infection (39,53-56). TZM-bl cells were transfected with 
non-tagged dyn I K44A from rat or HA-tagged dyn I K44A from human. The homology of 
two plasmids’ sequences was 91%. The inhibition on productive HIV-1 infection was then 
measured by counting blue cells that have been productively infected by NL4-3 virus, i.e., 
provirus has been integrated into cellular chromosomes, which upon transcriptional 
activation, produces Tat protein that subsequently activates the expression of β -
galactosidase (51).   
1, 2 or 5 µg of either dyn I K44A mutant or wild-type dyn I plasmid was transfected 
to TZM-bl cells for 24 hours and reseeded for measuring virus infection. Since the strong 
CMV promoter in dyn I K44A plasmid might cause beyond normal level of dynamin 
molecules inside cells, wild-type HA-tagged dyn I was used as a control. There were 30% 
inhibition on viral infection with dyn I K44A transfected TZM-bl cells compared to both 
pcDNA3.1(-) and wild-type dyn I transfected cells. Also, the fraction of inhibition on viral 
infection was similar among different amounts of each plasmid for both tagged and non-
tagged, suggesting that 1 µg of transfection was sufficient to block dynamin I (Figure 3.3A).  
 
3.4.3. Specificity of inhibition by dynamin I K44A on endocytosis  
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To provide further support for the role of dynamin-dependent endocytic pathway in 
productive HIV-1 infection, we meant to determine the phenotypic correlation between 
inhibition of dynamin-dependent endocytosis and inhibition of HIV-1 infection. 
Transferrin has been used as a conventional example for clathrin-dependent endocytosis 
with the fact that dynamin is necessary for clathrin-dependent coated vesicle formation 
during the process of vesicles pinching off from membrane (27). Transferrin binds at the 
cell surface to its corresponding receptor and is internalized by receptor-mediated 
endocytosis, a process that requires the formation of clathrin-coated pit (46,57-59).  
We used Alexa 488-transferrin conjugates to determine whether there is a decrease 
in the uptake and trafficking of transferrin upon dynamin I inhibition. We incubated 
transferrin at 37°C for 5 minutes with dyn I-transfected TZM-bl cells, followed by PBS 
and acid wash to detach membrane-bound transferrin (46,59). Only endocytosed Alexa 
488-transferrin conjugates were measured based on the intensity of each cell using a flow 
cytometer. Over the entire range of transfected amount of dyn I K44A investigated, we 
observed a similar decrease in the extent of endocytosed transferrin molecules (Figure 
3.5B). The inhibition of dyn I K44A on productive viral entry correlated with the decrease 
by about 30% in the transferrin uptake. Furthermore, this inhibition on the extent of 
endocytosed transferrin due to dynamin I mutants persisted for at least 78 hours post 
transfection (60), which is necessary for checking viral productive infection based on 
TZM-bl indicator cells (Figure 3.5C). Transfection of TZM-bl indicator cells by dyn I 
K44A, the dominant-negative mutant of dynamin I, decreased HIV-1 infection by ~30% 
(Figure 3.3A), which correlated with the decrease of endocytosis as monitored via 
transferrin uptake, suggesting that dynamin-dependent endocytosis contributes to the 
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productive infection of HIV-1. These studies were compared with VSV-G pseudotyped 
virions, which are known to enter cells through endocytosis (35). VSV-G pseudotyped 
virions also showed ~30-40% inhibition on transferrin uptake by dyn I K44A (Figure 3.3B).  
There was a correlation between the specific inhibition on dynamin-dependent 
endocytosis and the inhibition of viral infection (Figure 3.3A). Also, the extent of inhibition 
on viral infection by dyn I K44A was comparable between HIV-1 and VSV-G pseudotyped 
virion (Figure 3.3B). Moreover, not all TZM-bl cells were not transfected with dyn I K44A 
due to the limitation of transfection efficiency. The transfection efficiency might change 
the interpretation of data. Also, there were still residual fraction of endocytosis, as indicated 
by transferrin uptake, which was not blocked by dyn I K44A. Although less than 30% of 
TZM-bl cells were transfected and expressed dyn I or dyn I K44A (Figure 3.4B and C), we 
still saw the inhibition of viral infection by 30%. Thus, we concluded that about 30% of 
HIV-1 established productive infections via dynamin I -dependent endocytosis in our 
system using TZM-bl cells. This strongly suggests some extent of HIV-1 enter via 
dynamin-dependent endocytosis and leads to productive infections.  
 
3.4.4. Blocking various steps of endocytosis by inhibitors with different cell lines 
To investigate HIV-1 can enter and infect cells, several inhibitors related to different 
steps of entry were used with different cell lines. Dynasore interferes the GTPase activity 
of dynamin I and dynamin II, but not all other small GTPases (47). It has been used to 
claim HIV-1 can enter a cell via dynamin-dependent endocytosis (1). Chlorpromazine was 
also known to block the clathrin-dependent endocytosis, which is the major entry pathway 
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of VSV-G (35,61). Either entry mechanism, direct fusion on plasma membrane or 
endocytosis, membrane fusion between viral and cellular membranes is required for virus 
to productively infect host cells (6). Thus, T20, which displayed outstanding effects of 
fusion inhibition (36,37), was used as a positive control for inhibition on viral infection.  
First, we optimized the concentration of DEAE-dextran in each cell line based on 
the highest infectious virus concentration and no apparent cellular toxicity. We used 20 
µg/ml DEAE-dextran for TZM-bl, and 10 µg/ml for both SupT1 and Jurkat cell lines 
(Figure 3.1). The optimized concentration of DEAE-dextran for each cell line was used for 
further inhibition assay in this chapter 3. With all concentrations of DEAE-dextran, the 
fractions of live cells in terms of cellular permeability by trypan blue assay were above 95% 
except 20 µg/ml with Jurkat cells, which fraction was 73% (data not shown), resulting in 
picking up 10 µg/ml instead of 20 µg/ml. 
We pretreated various concentrations of dynasore with TZM-bl, Rev-CEM, and 
SupT1 cell lines before virus infection. Each concentration of dynasore were pretreated 
with each cell line for 30 minutes at 37°C. Since our measurement of inhibitory effects 
might be overestimated due to the decreased number of cells analyzed with a flow 
cytometer, we checked the cytotoxicity of inhibitors, such as dynasore, chlorpromazine, 
and T20 with each cell line. It is also necessary to see inhibitory effect of each drug on viral 
entry with the normal condition of cells. Thus, we checked both membrane permeability 
using trypan blue dye and cell growth counting the total number of cells which have been 
treated with inhibitors and incubated further same as the infection assay. Within the range 
of concentrations used in all graphs, cellular membrane permeability was above 95% (data 
not shown).  
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With TZM-bl cell line, we observed up to 50% inhibition on productive viral 
infections within the range of concentrations without apparent cytotoxicity in terms of 
cellular growth and membrane permeability (Figure 3.7A). Also, we were able to measure 
viral infection with Rev-CEM and SupT1 cell lines based on a mCherry signal since 
mCherry-labeled HIV-1 was inoculated and there is a linear correlation between the 
number of mCherry-positive cells and virus input (Figure 3.6A and B). Rev-CEM, which 
is a rev-dependent indicator T cell line (62), also showed up to 50% inhibition on viral 
infection based on both GFP and mCherry signals (Figure 3.7B). SupT1 cells showed up 
to 30% inhibition based on a mCherry signal (Figure 3.7C). The residual 50% or above of 
viral productive infections might be either from direct fusion events or endocytosis that 
cannot be blocked by dynasore with non-toxic concentration. We concluded some portion 
of endocytosis is strongly related to viral productive infection even though there was a 
difference in the extent of inhibition among cell lines and inhibition approach. 
Furthermore, VSV-G pseudotyped virions was also blocked by the similar extent 
with dynasore treatment in TZM-bl cell line (Figure 3.9B). Also, chlorpromazine, which is 
the molecule blocking clathrin-dependent endocytosis (61), was able to inhibit productive 
infection with both HIV-1 and VSV-G pseudotyped virions (Figure 3.9A). These results 
strongly suggest this inhibition of HIV-1 entry is related to inhibition on endocytosis. 
However, endocytosis may not be the only productive pathway for HIV-1 infection 
because all these inhibitions that we have observed appear to be partial, which is in sharp 
contrast to inhibition by T20.  T20 potently block almost all productive infections with 
three different cell lines (Figure 3.8A, B, and C). Even with the saturating concentration of 
T20 (1 µM), there were comparable endocytosed viral particles (data shown and discussed 
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in chapter 4), this may suggest that endocytosed virion needs to fuse with endosomal 
membrane for productive infection. Due to the partial inhibition on infection by blocking 
endocytosis, the specificity of inhibitors is critical for interpretation of these data.  
 
3.4.5. Off-target inhibition by dynasore on endocytosis to viral infection 
Both uptake and trafficking of transferrin were strongly blocked in cells preincubated 
for 30 minutes at 37°C with 80 µM of dynasore based on the studies (1,63) that first 
reported the discovery of dynasore molecule (47). However, there have been some studies 
showing that dynasore or other small molecules related to inhibition on receptor-mediated 
endocytosis was unable to antagonize transferrin uptake, suggesting a potential off-target 
effect of these inhibitors. To test the effect of dynasore on clathrin-dependent endocytosis, 
we incubated transferrin for various time periods at 37°C with TZM-bl cells pretreated with 
dynasore. First of all, we used 2 hours as incubation time for transferrin with cells, which 
was the same condition as inoculation when measuring viral infections (39). Over the entire 
range of concentrations of dynasore up to 200 µM investigated, we couldn’t see a decrease 
or trend in the extent of endocytosed transferrin molecules (Figure 3.5A). One possibility 
that we couldn’t detect the difference in intensity peak might be that 2 hours was too long 
to observe the difference that might be transient, as endocytosis could happen very fast. 
We have thus shortened the incubation time. However, even with 5 minutes as well as 30 
minutes, there was no apparent change in the intensity peak. Dynasore, a noncompetitive 
inhibitor of dynamin, inhibited HIV-1 infection in various cell lines (Figure 3.7A, B, and 
C), but this inhibition is not correlated with the reduction in transferrin uptake, suggesting 
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that dynasore inhibits HIV-1 infection through an off-target effect. The other recent study 
also suggested the off-target effect of dynasore by showing that dynasore cannot impair 
fluid-phase endocytosis and peripheral membrane ruffling which was blocked by cells 
having the lack of all three dynamins (64).   
 
3.4.6. Inhibitory effect of dynasore on viral infection in TZM-bl cells regardless of 
different facilitating methods for virus binding to cell surface and viral envelopes 
from different strains 
In order to overcome the apparent low infectivity of HIV-1 (65-71), polycations or 
spinoculation has been used for facilitating virus binding to a cell and increasing apparent 
infectivity (39,72). However, there is a possibility that the inhibitory effect of dynasore on 
viral infection in the presence of DEAE-dextran, whose optimized concentration we have 
used for our all infection assay, might have nonspecific effect. To exclude this possibility, 
TZM-bl cells, which had been pretreated with dynasore, were infected with HIV-1 virions 
in the absence or presence of DEAE-dextran (Figure 3.10A). Regardless of the presence of 
DEAE-dextran, dynasore indeed inhibited productive viral infection up to 50%. The other 
method, Spinoculation, which has been used for facilitating virus binding to cellular 
surface in the literature (72), was also tested with the fixed concentration of dynasore, 80 
µM. Figure 3.10B shows that dynasore inhibited viral infection by 20-30%, which is 
relatively consistent result with DEAE-dextran, in the presence of spinoculation in 1,200 
g for 2 hours, whose condition was described in the earler study (72).  
Furthermore, in our studies, we have extensively used NL4-3, which is an HIV-1 
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strain widely used for production of cloned HIV-1 virions (40-42). Since the inhibition on 
viral infection by dynasore might be envelope glycoprotein specific, we decided to test 
HXB2 envelope from different HIV strain (43). Indeed, dynasore can inhibit productive 
infection of HIV-1 carrying HXB2 envelope glycoproteins with either 20 µg/ml DEAE-
dextran or spinoculation (Figure 3.10B). Therefore, we concluded the inhibitory effect of 
dynasore on productive viral infection is due to the inhibition on endocytosis, but not the 
nonspecific effect of DEAE-dextran or spinoculation.  
 
3.5. Discussion  
Productive entry of HIV-1 into CD4+ T cells has not been clearly investigated yet. 
This question is fundamentally important for molecular understanding of HIV-1 
infection.  Early studies have suggested that HIV-1 can enter target cells via direct fusion 
at the plasma membrane (21,73,74). In contrast, recent studies have suggested that the 
direct fusion at the plasma membrane is not productive. Instead, HIV-1 may enter cells via 
dynamin-dependent endocytosis (1,2) and lead to a productive infection.   
First of all, we can clearly visualize HIV-1 virions colocalized with early endosomes 
(Figure 3.2A). Also, the fraction of colocalization was comparable with VSV-G 
pseudotyped virions (Figure 3.2C). This suggests the localized HIV-1 inside early 
endosomes may go to further productive infections based on the fact that VSV-G is able to 
cause infections via receptor-dependent endocytosis (35).   
To examine the extent to which endocytosis leads to productive infection of HIV-1, 
we have used several inhibitors of dynamin to investigate whether there is a correlation 
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between inhibition of HIV-1 infection and the inhibition of cell endocytosis. These studies 
were compared with VSV-G pseudotyped virions, which are known to enter cells through 
endocytosis (35). Transfection of TZM-bl indicator cells by dyn1 K44A, the dominant-
negative mutant of dynamin I, decreased HIV-1 infection by ~30% (Figure 3.3), which 
correlated with the decrease of endocytosis as monitored via transferrin uptake (Figure 
3.5B), suggesting that dynamin-dependent endocytosis contributes to the productive 
infection of HIV-1.  
Furthermore, dynasore, a noncompetitive inhibitor of dynamin (47), inhibited HIV-
1 infection in various cell lines (Figure 3.7A, B, and C), suggesting that endocytosis can 
indeed lead to productive infection, as revealed by the specific inhibition of HIV-1 
infectivity by the dyn I K44A mutant (Figure 3.3). The specificity of inhibitors is critical 
for interpretation of these data, and through this study we uncovered the off-target effect 
of dynasore (Figure 3.5A). Our all inhibition data showed partial inhibition on viral 
infection by blocking endocytosis due to cellular cytotoxicity with high concentrations of 
dynasore and chlorpromazine. However, there was no apparent difference in the extent of 
inhibition on viral infection between HIV-1 and VSV-G pseudotyped virion (Figure 3.9A 
and B). This also suggests that endocytosis can indeed contribute to productive infection. 
It would be required to knock down all 3 dynamin isoforms in order to definitively assess 
the effect of dynamin-dependent endocytosis on viral infection (64).  
Either direct fusion or endocytosis, there should be membrane fusion process 
between viral membrane and plasma/endosome membrane for viral productive infection 
(5,6). Interestingly, endocytosed HIV-1 can be clearly observed in SupT1 cells even in the 
presence of saturating T20 (data shown and discussed in chapter 4), suggesting that T20 
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may be endocytosed together with HIV-1 and exert its effect inside an endosome. However, 
endocytosis may not be the only productive pathway for HIV-1 infection because all these 
inhibitions that we have observed appear to be partial, which is in sharp contrast to 
inhibition by T20.  T20, the membrane-impermeable inhibitor of HIV-1 entry, potently 
inhibited HIV-1 infection in all cell lines investigated (Figure 3.8A, B, and C). These results 
also suggest that endocytosed virions need to fuse with endosomal membrane for 
productive infection.  Therefore, we concluded receptor-dependent endocytosis 
contributes to productive entry of HIV-1. Understanding of productive HIV-1 entry will 
help elucidate viral pathogenesis and further develop therapeutics that is aimed to block 
HIV entry to CD4+ T cells.  
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3.7 Figures 
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Figure 3.1. Optimization of DEAE-dextran concentration in TZM-bl, SupT1, and 
Jurkat cell lines.  
 
The optimized concentration of DEAE-dextran for each cell line was used for all inhibition 
assay in this chapter 3. (A) Optimized concentration of DEAE-dextran in TZM-bl cell line 
is 20 µg/ml under MOP 0.14 condition. (B) Optimized concentration of DEAE-dextran in 
SupT1 cell line is 10 µg/ml under MOP 170 condition. (C) Optimized concentration of 
DEAE-dextran in Jurkat cell line is 10 µg/ml under MOP 170 condition. All procedures 
followed the infection assays with each cell line described in Material and Methods. With 
all concentrations of DEAE-dextran, the fractions of live cells in terms of cellular 
permeability by trypan blue assay were above 95% except 20 µg/ml with Jurkat cells, 
whose fraction was 73% (data not shown), resulting in picking up 10 µg/ml instead of 20 
µg/ml. 
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Figure 3.2. Colocalization of HIV-1 or VSV-G pseudotyped virion with early 
endosomes.  
 
(A) Representative image for HIV-1 colocalization inside early endosomes. TZM-bl cells 
were inoculated with HIV-1 carrying free EGFPs for 30 minutes under MOP 200 condition. 
(B) Representative image for the colocalization of VSV-G pseudotyped virion inside early 
endosomes. TZM-bl cells were inoculated with VSV-G pseudotyped HIV-1 carrying free 
EGFPs for 30 minutes under MOP 200 condition. (C) Quantitation of colocalization with 
different inoculation time points was measured by the number of colocalized virions with 
early endosomes over the total number of fluorescent viral particles. Black squares (HIV-
1 carrying free EGFPs with 1 µg of NL4-3 ENV). Blue squares (VSV-G pseudotyped 
virions carrying free EGFPs with 1 µg of VSV-G ENV). Error bars were from five areas 
of confocal images. 
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Figure 3.3. Correlation between inhibition on productive infection and dynamin-
dependent endocytosis. 
 
(A) Fraction of blue cells with transfection of different amounts of plasmids. Black bar 
(pcDNA 3.1(-), 2 µg). Gray bar (wild-type HA-tagged dyn I, 2 µg). Filled squares (HA-
tagged dyn I K44A from rat). Open circles (Non-tagged dyn I K44A from human). (B) 
Fraction of blue cells in TZM-bl cells by using different viral envelope transfected with 2 
µg of each plasmid. Filled squares (HIV-1 carrying free EGFPs with 1 µg of NL4-3 ENV). 
Open diamonds (VSV-G pseudotyped virions carrying free EGFPs with 1 µg of VSV-G 
ENV). Error bars were from duplicates of transfection and blue cell counting.  
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Figure 3.4. Transfection efficiency of dyn I-EGFP or dyn I K44A-EGFP in TZM-bl 
cells. 
 
Representative images of flow cytometry (A) Negative control. TZM-bl cells were 
transfected for 24 hours with 2 µg of pcDNA 3.1(-). (B) 2 µg of dyn I-EGFP. (C) 2 µg of 
dyn I K44A-EGFP. 
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Figure 3.5. Specificity of inhibition on endocytosis in TZM-bl cells by measuring the 
uptake of Alexa 488-transferrin conjugate. 
 
(A) Quantification of transferrin uptake in TZM-bl cells with different concentrations of 
dynasore treatment. The uptake was normalized based on a control without dynasore 
treatment. White bar (transferrin uptake at 37°C). Black bar (Negligible transferrin uptake 
at 4°C). (B) Measurement of transferrin uptake in TZM-bl cells transfected with different 
amounts of dyn I K44A plasmids. Open bar (pcDNA 3.1(-)). Filled squares (HA-tagged 
dyn I K44A from human). Open circles (Non-tagged dyn I K44A from rat). (C) 
Quantification of transferrin uptake in TZM-bl cells transfected with 2 µg of each plasmid 
using different time points. The effect of transfection persisted up to 78 hours post 
transfection. Open bars (30 hours post transfection). Gray bars (54 hours post transfection). 
Black bars (78 hours post transfection). Error bars were from the duplicate of same 
experiments.  
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Figure 3.6. Correlation between productive infection and virus concentration based 
on mCherry signals.  
 
The number of mCherry positive cells were quantitated with a flow cytometer using a 561 
nm laser with various virus input. (A) Linear relationship between the number of mCherry 
positive cells and virus concentration in Rev-CEM cells. (B) Linear relationship between 
the number of mCherry positive cells and virus concentration in SupT1 cells. HIV-1 
carrying free mCherrys in 100 µl was used. Error bars were from triplicates in the same 
experiment.  
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Figure 3.7. Measurement of inhibition on productive infections using dynasore in 
TZM-bl, Rev-CEM, and SupT1 cell lines.  
 
Inhibition on productive infections by dynasore pretreatment in different cell lines. (A) 
Normalized productive infections by blue cell counting in TZM-bl with dynasore treatment. 
(B) Normalized infections in Rev-CEM based on the number of GFP or mCherry positive 
cells with dynasore treatment. Black circles (mCherry signasl). Open diamonds (EGFP 
signals). (C) Normalized infections in SupT1 based on the number of mCherry positive 
cells with dynasore treatment. All experiments used HIV-1 carrying free mCherrys. All 
white bars represent the growth normalized based on controls without dynasore 
pretreatment. Error bars were from triplicates. Within the range of concentrations, cellular 
permeability was above 95% by trypan blue assay (data not shown).   
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Figure 3.8. Measurement of inhibition on productive infections using T20 in TZM-bl, 
Rev-CEM, and SupT1 cell lines.  
 
Inhibition on productive infections by T20 in different cell lines. (A) Normalized 
productive infections by blue cell counting in TZM-bl with T20 treatment. (B) Normalized 
infections in Rev-CEM based on the number of GFP or mCherry positive cells with T20 
treatment. Black circles (mCherry signasl). Open diamonds (EGFP signals). (C) 
Normalized infections in SupT1 based on the number of mCherry positive cells with T20 
treatment. All experiments used HIV-1 carrying free mCherrys. All white bars represent 
the growth normalized based on controls without T20 pretreatment. No apparent T20 
toxicity in terms of cellular growth on three different cell lines within the range of 
concentrations used. Error bars were from triplicates. Within the range of concentrations, 
cellular permeability was above 95% by trypan blue assay (data not shown).   
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Figure 3.9. Measurement of inhibition on productive infections in TZM-bl by 
chlorpromazine or dynasore with HIV-1 or VSV-G pseudotyped virions.  
 
Productive infections were measured by blue cell counting in TZM-bl cell line. (A) 
Measurement of productive infection in TZM-bl cells using chlorpromazine. (B) 
Measurement of productive infection in TZM-bl cells using dynasore. Filled squares (HIV-
1 carrying free EGFPs with 1 µg of NL4-3 ENV). Open circles (VSV-G pseudotyped 
virions carrying free EGFPs with 1 µg of VSV-G ENV). Error bars were from duplicates 
of blue cell counting and growth cell counting. All white bars represent the growth 
normalized based on controls without each inhibitor. Within the range of concentrations, 
cellular permeability was above 95% by trypan blue assay. 
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Figure 3.10. Inhibitory effect of dynasore on viral infection in TZM-bl cells regardless 
of different facilitating methods for virus binding to cell surface and viral envelopes 
from different strains 
 
(A) Inhibition on productive infections by dynasore pretreatment in TZM-bl cell line in the 
absence or presence of DEAE-dextran. All white bars represent the growth normalized 
based on controls without dynasore pretreatment. Within the range of concentrations, 
cellular permeability was above 95% by trypan blue assay (data not shown). (B) Either 20 
µg/ml DEAE-dextran (D) or spinoculation (S) was used for facilitating virus binding to 
host cells. HIV-1 was produced with 1 µg pNL4-3R¯E¯, 0.3 µg EGFP-Vpr, and 0.1 µg 
pcDNA3.1REC/NL4-3 or pcDNA3.1REC/HXB2. Error bars were from duplicates.  
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Chapter 4. 
 
Impact of Virion Endocytosis on Membrane-
impermeable HIV-1 Drugs 
 
4.1. Abstract 
To determine if virion endocytosis can lead to productive infection, we used various 
inhibitors that are known to block various steps of endocytosis. The results from three 
different cell lines suggest that endocytosis can indeed lead to productive infection, as 
revealed by the specific inhibition of HIV-1 infectivity by the dynamin I K44A mutant 
(discussed in chapter 3). However, endocytosis may not be the only productive pathway 
for HIV-1 infection because all these inhibitions that we have observed appear to be partial, 
which is in sharp contrast to inhibition by fusion inhibitor, T20. These results also suggest 
that endocytosed virion needs to fuse with endosomal membrane for productive infection. 
In comparison to direct fusion at the plasma membrane, endocytosis may allow virus to 
escape from membrane impermeable drugs (1, 2). The conclusion that endocytosis can 
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cause productive infection of HIV-1 virions in chapter 3 led us to investigate whether 
endocytosis affects membrane-impermeable drugs of HIV-1.  
To address this question, we have tested both neutralizing antibodies and T20, and 
further focused on T20 to dissect the mechanisms of inhibition. There was no effect of T20 
on HIV internalization by observing and analyzing confocal images. To further investigate 
the impact of endocytosis on the efficacy of T20, we did titration of T20 and also varied 
the time of addition for T20 with regard to virion infection by TZM-bl cells, whose 
endocytic activity had been inhibited. These experiments showed that endocytosis has no 
apparent effect on T20 efficacy, suggesting that endocytosis does not offer any measurable 
advantage for virus to escape. As a matter of fact, for both antibodies and T20, HIV-1 
infection can be blocked close to 100%, indicating that these drugs are efficacious enough 
in vitro even though HIV can establish productive infection through endocytosis. Future 
experiments for the mechanism of T20 will be the colocalization studies between virions 
and anti-CD4 or fluorescently-labeled T20 inside endosomes in order to investigate the 
hypothesis that membrane-impermeable drugs exert its inhibitory effect on viral fusion 
within the endosome as virus bound to CXCR4 coreceptor followed by the engagement 
between CD4 receptor and gp120. 
 
 
4.2. Introduction 
HIV-1 has rapidly evolved due to the size of the viral population in individual 
patients (3, 4), extensive recombination (5, 6), and the high rate of viral replication, which 
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contributes to genetic variation (7, 8). This can cause a considerable challenge for anti HIV-
1 drugs development (9). During HIV-1 infection, almost all individuals produce 
antibodies to viral envelope glyocoproteins, but only a small fraction can neutralize the 
virus (10, 11). Recently, several studies have shown that the sera of 10 to 25% of infected 
patients contain broadly reactive neutralizing antibodies (NAbs) for various primary strains 
of HIV-1 (12-16). Initially, the mechanism of this serum neutralization was poorly 
understood; however, it was revealed that viral neutralization epitopes came from the 
isolation of neutralizing human monoclonal antibodies (mAbs). These mAbs targeted three 
distinct regions of the viral envelope: the CD4 binding site of gp120 (b12), surface glycans 
on the outer domain of gp120 (2G12), and the membrane proximal external region of gp41, 
just prior to the transmembrane spanning sequence (2F5, 4E10, and Z13e). However, none 
of the above broadly neutralizing antibodies was able to neutralize the majority of diverse 
HIV-1 strains even with additional HIV-1 isolates from geographically various regions 
(17). 
The envelope glycoprotein complex is indispensable to HIV-1 entry into cells by 
mediating the viral attachment to target cells and subsequent membrane fusion. Several 
steps of the entry process can be targets of antiviral drug development. Receptor 
antagonists prevent attachment of gp120 to the receptor or coreceptor, and conformational 
changes within gp41 required for membrane fusion can be blocked by fusion inhibitors. 
The first fusion inhibitor developed was peptide mimics of the HR2 (heptad repeat domain 
2) sequence of gp41 that act by competitively binding to HR1 (heptad repeat domain 1). 
T20 (Enfuvirtide/Fuzeon, Roche/Trimeris) is a 36 amino acid peptide corresponding to the 
gp41 amino acid sequence of the HXB2 isolate, shifted several residues along the HR2 
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sequence with respect to each other (18-24). This peptide inhibits virus entry by binding to 
the HR1 core that is formed after binding of gp120 to CD4 and the coreceptor, thereby 
blocking the subsequent formation of the six-helix bundle (18, 24-26). It is active in the 
nanomolar range against various HIV strains and blocks virus infection of cells and viral 
spread via cell-cell contact, which may be the more physiological route (18-24, 27). T20 
has been used as a salvage therapy for patients who have developed a resistance issue with 
highly active antiretroviral therapy (HARRT), which is a combination of several drugs that 
aims to control the amount of virus in patients’ body (28, 29). It was approved for clinical 
use in March 2003 by the US Food and Drug Administration (FDA) and the European 
Medicines Agency (EMEA). T20, however, needs to be subcutaneously injected to reach 
a sufficiently high blood level for inhibiting viral infection and also causes common 
symptoms on the injection site (30-34). Thus, there are ongoing studies to develop the new 
generations of T20-like peptides with improved potency, stability, and formulation (35, 
36). Besides T20 and derivatives, other fusion inhibitors have been developed that target 
different domains of gp41 (36, 37).   
Although there have been promising data in the early phase I and II clinical trials, 
the company, Roche/Trimeris decided to stop developing further clinical trials for the next 
generation of fusion inhibitors. This decision was “due to challenges with achieving the 
technical profile required of the current investigational formulation of T1249”. The 
company emphasized that the “current formulation of T1249 would not be suitable for 
large scale clinical use” (38). However, T20 was the first new class of HIV inhibitors 
targeting the viral entry step. T20 was therefore a promising ingredient of a therapeutic 
salvage regimen (39) since T20 action is not affected by the presence of resistance 
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mutations against protease and reverse transcriptase inhibitors. Thus, research on the next 
generation of fusion inhibitors, which optimally have enhanced efficacy, a higher genetic 
barrier to resistance issue, less frequent subcutaneous administration, and combined with 
the use of new formulation methods will help prevent both chronic and acute viral 
infections.  
In this study, we hypothesized that virion endocytosis offer an advantage for virus 
to escape from membrane-impermeable antiviral drugs, such as broadly neutralizing 
antibodies, or specifically T20. Otherwise, it may exert its inhibitory effect on viral 
infections as endocytosed together with virions in endosomes. The results from three 
different cell lines suggest that endocytosis can indeed lead to productive infection, as 
revealed by the specific inhibition of HIV-1 infectivity by the dynamin K44A mutant 
(discussed in chapter 3). However, endocytosis may not be the only productive pathway 
for HIV-1 infection because all these inhibitions that we have observed appear to be partial, 
which is in sharp contrast to inhibition by T20. These results also suggest that endocytosed 
virion needs to fuse with endosomal membrane for productive infection. In comparison to 
direct fusion, endocytosis may allow virus to escape from membrane impermeable drugs 
(1, 2). To test this hypothesis, we observed the effect of T20 on the internalization of HIV-
1 by analyzing confocal images. To further investigate the impact of endocytosis on the 
efficacy of T20, we did titration of T20 and also varied the time of addition for T20 with 
regard to virion infection by TZM-bl cells, whose endocytic activity had been 
inhibited. Investigating the behavior and mechanism of T20 is fundamentally important for 
molecular understanding of HIV-1 entry as well as developing the new generations of T20-
like antiviral HIV-1 drugs.    
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4.3. Materials and Methods 
Virus production 
HEK 293T/17 cells (AYCC, Manassas, VA) were cultured at 37°C with 5% of CO2 
in media including 90% of DMEM and 10% of FBS (HyClone, Laboratories, Logan, UT). 
All cells for virus production were less than five times passaged. To produce single-cycle 
HIV-1 virions, 106 293T cells in 2-ml were seeded, settled overnight in 6-well plate and 
transfected with necessary plasmids using TransIT LT-1 transfection reagent (Mirus Bio, 
Madison, WI). For each well, 1 µg of proviral DNA as pNL4-3R¯E¯ was used together 
with various amount of envelope expression plasmid, pcDNA3.1REC and 0.3 µg of 
pEGFP-Vpr. HIV-1 virions carrying 50% free EGFPs were produced with 0.5 µg of pNL4-
3E¯ and 0.5 µg of pNL4-3E¯MA-EGFP-CA plasmids with various amount of 
pcDNA3.1REC. The amount of plasmids for EGFP tags was determined based on the 
highest concentration of infectious virus particles (Ci.p.) (discussed in chapter 2) (40). The 
entire culture media including virus was replaced at 6 hours post transfection, collected 
and filtered using a 0.45-µm syringe filter (Millex-HV PVDF, Millipore) at 24 post 
transfection for EGFP-Vpr HIV-1. For free EGFP tagged virions, 18 hours was used as a 
harvesting time. All virus samples were flash frozen and stored -80°C. All detailed 
transfection and virus preparation procedures followed the protocol described earlier in our 
work (40). 
To produce T cell-derived virions, 2X106 Jurkat cells in 1-ml were transfected with 
0.5 µg of pNL4-3E¯ and 0.5 µg of pNL4-3E¯MA-EGFP-CA plasmids with 1 µg 
pcDNA3.1REC. 2 µl of TransIT-Jurkat transfection reagent (Mirus Bio, Madison, WI) 
with 1 µg of DNA was used for the highest transfection efficiency. They were harvested 
113 
 
for 72 hours, centrifuged down in 300 g for 5 minutes, and filtered using a 0.45-µm syringe 
filter. Virus samples were then flash frozen and stored -80°C.  
 
Measuring the inhibition on virus infection by membrane-impermeable drugs 8X104 TZM-bl cells were seeded in 12-well plate and cultured overnight at 37°C 
with 5% of CO2 in media including 90% of DMEM and 10% of FBS. VRC03 (cat#12032, 
NIH AIDS Research and Reference Reagent Program), VRC01 (cat#12033), and b12 
(cat#2640) were used as neutralizing antibodies (NAb). Virions carrying EGFP-Vpr in 40 
µl was incubated with each concentration of antibodies in 10 µl for 1 hour at room 
temperature. The concentration of NAbs in Figure 4.1A and B was based on the 
concentration during preincubation step. The virion-NAb complex was then diluted with 
complete media including 20 µg/ml DEAE-dextran without vortexing, and inoculated with 
TZM-bl cells for 2 hours with every 30 min gentle rocking. In the case of T20, which acts 
on virus, cells were inoculated with a mixture of virus and certain concentration of T20 
instead of pretreatment. Inoculation was done at 37°C for 2 hours with every 30 minutes 
rocking in the presence of 20 µg/ml DEAE-dextran. After 2 hours inoculation, inoculum 
was removed and cells were washed with using complete media once. Cells were further 
incubated for 2 days at 37°C by adding 1-ml of complete media. Cells were then fixed with 
2% gluteraldehyde for 5 minutes at room temperature, and stained using β-galactosidase 
staining kit (Mirus Bio, Madison, WI) for 50 minutes at 37°C. The inhibition data was 
calculated by normalizing the number of blue cells in each well compared to TZM-bl 
inoculated with virions which had not been pretreated or premixed with neutralizing 
antibodies or T20.  
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Confocal imaging to classifying and quantitating the location of virions 
SupT1 cells (cat#100, NIH AIDS Research and Reference Reagent Program) were 
cultured at 37°C with 5% of CO2 in medium including 90% of RPMI and 10% of FBS. 
2X105 SupT1 cells in 200 µl were inoculated with virions carrying free EGFPs derived 
from 293T or Jurkat for 30 minutes, 2 or 4 hours with automatic rocking. 10 µg/ml DEAE-
dextran was used with virus inoculation in SupT1 cell line, which was optimized previously 
(Figure 3.1). The virion in 100 µl was prepared as mixture with 1 µM T20, which is the 
saturating concentration in SupT1 cell line (Figure 3.8C). Free virions after inoculation 
were removed by washing with 300 µl of complete media using 300 g for 5 minutes. Cells 
were resuspended with l-ml of complete media and deposited on PLL-coated coverslip with 
1,000 g for 5 minutes. Supernatant was removed and the coverslip was fixed with 4% 
paraformaldehyde for 10 minutes at room temperature. Cells were stained with 1,000 fold 
diluted Cholera Toxin Subunit B with alexa fluorophore 555 conjugate (Invitrogen), which 
was dissolved in phosphate buffered saline (PBS) as 1 µg/µl, and stored at -80°C freezer. 
The coverslip was then washed with PBS and mounted onto a glass cover slide with 3 µl 
mounting media, sealed with nail polish, and imaged using an Olympus FluoView 500 
Laser Scanning Confocal Microscope.  
The virions and cellular membrane in a fluorescence image were identified and the 
location of virions can be categorized as inside, outside, or on the cell surface using a 
custom-written MATLAB script. Since the many virions can be imaged on several near 
slices of confocal images, we need to determine the exact location of actual fluorescent 
virus particles. In order to correlate between virion regions and slices, we found all 
overlapping virions regions by globally finding the shortest centroid-to-centroid distances 
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and relabeled virion regions, which has the highest intensity. Also, a cell whose membranes 
stained by Cholera Toxin B-Alexa 555 conjugate can usually be detected using edge 
detection method and basic morphology given sufficient contrast. Detected cellular 
boundaries can be further dilated or eroded by a certain pixel size. Based on our several 
trials using different pixel sizes to see whether there is a significant difference in the 
fraction of virions inside cells, there was no apparent differences. We decided to use 5 
pixels for dilation and 1 pixel for erosion based on the nearest boundaries between stained 
and detected membranes (data not shown). All confocal images were collected with 100X 
objective and 250 nm step size. From five to seven different areas on the same coverslip 
were collected for each data point.  
 
Measuring the impact of endocytosis on T20 efficacy 8X104 TZM-bl cells in 1-ml were seeded in 12-well plate and cultured overnight at 
37°C. Complete media was removed and 100 µl of complete media containing 80 µM 
dynasore was pretreated with TZM-bl cells for 30 minutes at 37°C. Dynasore was removed 
and cells were washed once. Then cells were inoculated with a mixture of virus and certain 
concentration of T20 instead of pretreatment. Inoculation was done at 37°C for 2 hours 
with every 15 minutes rocking in the presence of 20 µg/ml DEAE-dextran. Cells were 
further incubated for 2 days at 37°C by adding 1-ml of complete media. Cells were then 
fixed with 2% gluteraldehyde for 5 minutes at room temperature, and stained using β-
galactosidase staining kit 50 minutes at 37°C. The number of blue cells were counted with 
a microscope. The inhibition data was normalized with two different ways. One is singly 
normalized to no dynasore control. The other is normalized to no dynasore without T20. 
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For measuring the effect of endocytosis inhibition by dyn I K44A on T20 efficacy, 
we transfected TZM-bl cells for 24 hours with 2 µg of each plasmid, pcDNA3.1(-), non-
tagged dyn I K44A from rat, or HA-tagged dyn I K44A from human. We used TransIT 
LT-1 as a transfection reagent (Mirus Bio, Madison, WI). Then, cells were trypsinized and 8X104 cells in 1-ml were seeded in 12-well plate and settled at 37°C. After 6 hours, 
complete media was removed and cells were inoculated with 100 µl of diluted HIV-1. 
Inoculation was done at 37°C for 2 hours with every 15 minutes rocking in the presence of 
20 µg/ml DEAE-dextran. Cells were further incubated for 2 days at 37°C by adding 1-ml 
of complete media. Further assay was the same as previous experiments. The number of 
blue cells were counted with a microscope. The inhibition data was normalized with two 
different ways. One is singly normalized to pcDNA3.1(-) transfection control. The other is 
normalized to pcDNA3.1(-) transfected cells without T20. 
 
T20 efficacy with different time points T20 added 8X104 TZM-bl cells in 1-ml were seeded in 12-well plate and cultured overnight at 
37°C. Complete media was removed and 100 µl of complete media containing 80 µM 
dynasore was pretreated with TZM-bl cells for 30 minutes at 37°C. Dynasore was removed 
and inoculation was done at 37°C for 2 hours with every 15 minutes rocking in the presence 
of 20 µg/ml DEAE-dextran. 100 nM T20 in 10 µl added and mixed well to cells (with virus) 
at different time points from 0 minutes to 2 hours during 2 hours inoculation time. Cells 
were further incubated for 2 days at 37°C by adding 1-ml of complete media. Cells were 
then fixed with 2% gluteraldehyde for 5 minutes at room temperature, and stained using β-
galactosidase staining kit 50 minutes at 37°C. The number of blue cells were counted with 
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a microscope. The inhibition data was normalized with two different ways as the same 
discussed above. 
For measuring the effect of endocytosis inhibition by dyn I K44A on T20 efficacy 
with different time points T20 added, we transfected TZM-bl cells for 24 hours with 2 µg 
of each plasmid, pcDNA3.1(-), non-tagged dyn I K44A from rat, or HA-tagged dyn I K44A 
from human. We used TransIT LT-1 as a transfection reagent. Then, cells were trypsinized 
and 8X104 cells in 1-ml were seeded in 12-well plate and settled at 37°C. After 6 hours, 
complete media was removed and cells were inoculated with 100 µl of diluted HIV-1. 
Inoculation was done at 37°C for 2 hours with every 15 minutes rocking in the presence of 
20 µg/ml DEAE-dextran. Cells were further incubated for 2 days at 37°C by adding 1-ml 
of complete media. Further assay was the same as previous experiments. The number of 
blue cells can be singly normalized to pcDNA3.1(-) transfection control or respectively 
normalized to pcDNA3.1(-) transfected cells without T20. 
 
4.4. Results 
4.4.1. Potency of membrane-impermeable HIV-1 entry inhibitors 
Broadly neutralizing antibodies have known to efficiently block viral envelope, 
either gp120 or gp41, to interact with its corresponding receptor. T20 is also one of the 
potent antiviral drugs and it is a 36 amino acid synthetic peptide homologous to gp41 and 
first fusion inhibitor clinically approved by FDA (29, 41). Although both neutralizing 
antibodies and fusion inhibitors are membrane-impermeable, they are a potent drugs in 
vitro (9, 42). Based on our observation that endocytosis lead to productive viral entry, we 
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hypothesized that membrane-impermeable drugs exert its inhibitory effect on viral fusion 
within the endosome as virus bound to CXCR4 coreceptor followed by the engagement 
between CD4 receptor and gp120. As shown in Figure 4.1A and B, VRC03 and b12 
inhibited viral infections close to 100% regardless of their fluorescence tags although 
fluorescent-tagged antibodies needed higher concentrations for neutralization. T20 also 
showed a good efficacy on viral infection (Figure 4.1C), which was also confirmed with 
Rev-CEM and SupT1 cell lines in chapter 3. With our results, 1 µM T20 is enough to block 
almost all viral infections in TZM-bl, Rev-CEM, and SupT1 cell lines (Figure 3.7 and 
Figure 4.1). 
 
4.4.2. Quantitation of virion internalization with T20 treatment  
Based on our observation that endocytosis lead to productive viral entry, we 
hypothesized that membrane-impermeable drugs may be able to enter cells and inhibit viral 
fusion within the endosome as virus bound to CXCR4 coreceptor followed by the 
interaction between CD4 receptor and gp120. With further imaging experiments, even with 
saturated condition for all productive infections by T20, there were still many endocytosed 
virions inside cells (Figure 4.2B), which also led to our hypothesis that T20 might be able 
to block a fusion event between viral and endosomal membranes. If there is a direct fusion 
event of free EGFP-tagged virus at the plasma membrane, the signals from it will quickly 
disappear and not be detected due to infinite dilution with the plasma membrane and 
cytosol (43). Thus, we expected to see the higher fraction of virion internalization inside 
cells with T20 allowing no fusion events. The fraction of internalized virions was measured 
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as the number of internalized one divided by the total number of virus particles in a field 
of view (FOV). We are able to exclude the possibility that all productive infections are via 
a direct fusion at the plasma membrane, then all endocytosed virus particles are towards a 
nonproductive pathway, based on our previous data (discussed in chapter 3). With a 
custom-written MATLAB manuscript, we can classify the location of fluorescent virus 
particles based on the cellular plasma membrane. They can be located inside a cell, outside 
a cell, or as bound to cellular membrane.  
First of all, the fraction of internalized gag particles, which don’t have viral envelope 
on virion surface required for receptor-mediated endocytosis, was above 10% in different 
inoculation time points (Figure 4.3A). It is not significantly different from the fraction of 
virion internalization (Figure 4.3B and C). Therefore, more than half fraction of virion 
internalization can be nonspecifically endocytosed through receptor-independent 
endocytosis.  
However, this phenomena might be due to host proteins of 293T cell line, which is 
used for virion production and is not a natural target/producer cell for HIV-1. The 
mechanisms of endocytic entries are uncertain. Whether they are mediated by gp120 or 
other host proteins on viral surface remains to be determined. In order to confirm whether 
the receptor-independent endocytosis we observed is host proteins-specific or not, we 
produced virions from Jurkat T cell line and conducted the same experiment as the above. 
The result from T cell-derived virions also showed that gag particles enter cells via 
receptor-independent pathway based on the similar fraction of virion internalization 
compared to virions carrying viral envelope regardless of the presence of T20 (Figure 4.4A 
and B).  
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Also, since we’ve not seen an apparent difference in the fraction of virus inside cells 
with 2 hours as inoculation time point, we decided to try 30 minutes and 4 hours as shorter 
and longer time points. Endocytosis is quite fast event, so we might not be able to capture 
the earlier fusion events. However, it turned out that there were statistically comparable 
fractions of internalized virions regardless of inoculation time points and T20 treatment 
(Figure 4.3B and C), suggesting that endocytosed virions are long-lived, which was also 
observed in TZM-bl cells (data not shown). One possible reason we couldn’t see the 
difference is that the fusion events might be very low probability due to low infectivity. 
Based on these data, we concluded that endocytosed virus particles all progressed towards 
non-productive infection pathways in the presence of T20 and those inside endosomes have 
relatively long lifetime.  
The above results generated several hypotheses that can be further tested. One of the 
possible experiments is to observe the colocalization of FITC-T20 and mCherry-labeled 
virus together with endosome markers using a microscope, which has resolution to resolve 
single fluorophores in mammalian cells. This will permit imaging of FITC-T20 since 
FITC-labeled virions cannot be observed in a confocal microscope without a resolution for 
single fluorophores.  
 
4.4.3. Effect of T20 on virion endocytosis 
The conclusion that endocytosis can cause productive infection of HIV-1 virions in 
chapter 3 led us to investigate whether endocytosis affects membrane-impermeable drugs 
of HIV-1.  
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To test this hypothesis, we have tested the effect of T20 on the internalization of HIV-1 by 
analyzing confocal images. As shown in Figure 4.3, there was no measurable effect of T20 
on virion endocytosis regardless of the presence of viral envelope, the input of viral 
envelope, and different inoculation time points. Although we concluded we were not able 
to see the difference in the fraction of virion internalization between the absence and 
presence of 1 µM T20, the effect of T20 on virion internalization was not apparent. This 
phenomena was also confirmed with T cell-derived HIV-1 virions (Figure 4.4).  
 
4.4.4. Impact of virion endocytosis on membrane impermeable HIV-1 drugs 
It has been suggested in literature that endocytosis may allow virions to escape from 
the action of membrane-impermeable drugs (1, 2). To test whether endocytosis affects 
membrane-impermeable drugs of HIV-1, we did titration of T20 with dynasore-pretreated 
or dyn I K44A transfected TZM-bl cells.  
TZM-bl cells were pretreated with 80 µM dynasore for 30 mintutes and dynasore 
was then removed. Cells were inoculated with virions in the presence of different 
concentrations of T20. Figure 4.5A showed the fraction of blue cells singly normalized to 
TZM-bl cells which had not been pretreated with dynasore. Consistently, there were ~30% 
inhibition on viral infection with 80 µM dynasore in the absence of T20 (Figure 3.7A). If 
we normalized the fraction of blue cells respect to each without T20, there was no 
difference in the efficacy of T20 between TZM-bl cells without dynasore pretreatment and 
cells whose endocytosis had been inhibited by dynasore (Figure 4.5B). For more specific 
manner, TZM-bl cells were transfected with two different dyn I K44A for 24 hours, 
122 
 
trypsinized, and settled for further infection assay. As shown in Figure 4.6A, the fraction 
of blue cells, which was singly normalized to TZM-bl cells which had been transfected 
with pcDNA3.1(-) also showed ~30% inhibition in the absence of T20 (consistent with 
Figure 3.3). If we respectively normalized the fraction of blue cells based on the absence 
of T20, T20 efficacy was similar regaredless of the inhibition on cell endocytosis by dyn I 
K44A (Figure 4.6B). Thus, endocytosis doesn’t offer measurable advantages for virus to 
escape from T20.  
 
4.4.5. T20 efficacy with different time points added 
Since we observed that there was no apparent difference in T20 efficacy with 
inhibition on endocytosis by either dynasore or dyn I K44A, we hypothesized that T20 
efficacy might be more related to T20 addition time.  
We varied the time of 100nM T20 addition during virion inoculation. Consistently, 
if we varied the addition time of the mixture of virus and 100 nM of T20, which was shown 
at zero in the x-axis, there was ~50% inhibition on viral infection (Figure 4.1C and Figure 
4.7). However, T20 efficacy dropped when we added T20 later during 2 hours inoculation 
window, suggesting T20 efficacy was different with T20 addition time (Figure 4.7 and 4.8). 
We have tested T20 efficacy in TZM-bl cells, whose endocytosis inhibited by dynasore or 
dyn I K44A, by varying the time of T20 addition.  
The fraction of blue cells decreased by 30% in TZM-bl cells, which had been 
pretreated with dynasore (Figure 4.7A). When we normalized the number of blue cells with 
respect to each without T20, the fraction of blue cells was comparable in TZM-bl cells 
regardless of endocytosis inhibition (Figure 4.7B). This phenomena were also confirmed 
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when using TZM-bl cells transfected with each dyn I K44A. These experiments also 
showed that endocytosis has no apparent effect on T20 efficacy, suggesting that 
endocytosis does not offer an apparent advantage for virus to escape from membrane 
impermeable T20. There could be two mechanisms of T20. One possibility is that T20 
blocks viral fusion at the site of action which is outside of the plasma membrane. The other 
mechanism is that T20 can be co-internalize with virus and exhibit inhibitory action within 
an endosome. For T20, we found that HIV-1 still undergoes endocytosis in the presence of 
saturating T20, suggesting the latter mechanism. However, there is one possibility for the 
former mechanism. The endocytosis in the presence of T20 are all receptor-independent 
and nonspecific. In order to exclude this, future experiment would be the colocalization 
studies of virions with anti-CD4 in an endosome. 
 
4.5. Discussion  
Some studies have suggested that endocytosis may allow virions to escape from the 
action of membrane-impermeable drugs (1, 2).  The conclusion that endocytosis can 
contribute to productive infection of HIV-1 virions (discussed in chapter 3) leads to our 
investigation in this chapter: what is the impact of endocytosis on membrane impermeable 
drugs of HIV-1? To address this question, we have tested both neutralizing antibodies and 
one of the fusion inhibitors, T20, and further focused on T20 to dissect the mechanisms of 
inhibition.   
First of all, both antibodies and T20 can block viral infections close to 100%, 
indicating that these drugs are efficacious enough in vitro even though HIV-1 can establish 
124 
 
productive infection through endocytosis, which was the conclusion from chapter 3. To 
test the hypothesis that endocytosis may allow virus to escape from membrane-
impermeable drugs, we have tested the effect of T20 on the internalization of HIV-1 by 
analyzing confocal images. To further investigate the impact of endocytosis on the efficacy 
of T20, we did titration of T20 and also varied the time of addition for T20 with regard to 
virion infection by TZM-bl cells, whose endocytic activity had been inhibited. These 
experiments showed that T20 doesn’t affect virion endocytosis and endocytosis has no 
apparent impact on T20 efficacy. It suggests that endocytosis does not offer measurable 
advantages for virus to escape from membrane-impermeable T20.  
Since T20 is membrane-impermeable, there are two possible explanations for the 
above phenomena. T20 can block HIV-1 infection at the site of action outside of the plasma 
membrane. Otherwise, it might be co-internalize with virus and exhibit inhibitory action 
within an endosome. For T20, we observed many endocytosed HIV-1 in the presence of 
saturating T20, suggesting the latter mechanism. However, one possibility for the first 
mechanism is that the events of virion endocytosis in the presence of T20 are all receptor-
independent and nonspecific. The possible experiment will be the colocalization of virions 
with anti-CD4 in an endosome.  
The mechanism of T20 has been proposed that it binds to a region of gp41 that 
mediates the conformational change from pre-hairpin intermediate to the fusion-active 
structure based on its sequences homologous to C-terminal heptad repeat (CHR) region. 
Contrary to this belief, there are several studies suggesting other mechanisms of T20: T20 
cannot inhibit the formation of stable six-helix bundles with N-peptides coming from N-
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terminal heptad repeat (NHR) region, which is supposed to make stable six-helix bundle 
with CHR region; second, it is not able to block six-helix bundle formation of the fusogenic 
core; third, T20 efficacy can be significantly abrogated by peptides derived from the 
membrane-spanning domain in gp41 and coreceptor binding site in gp120 (28, 37). These 
data suggest that T20 inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. 
Investigating the behavior and mechanism of T20 is fundamentally important for molecular 
understanding of HIV-1 entry as well as developing the new generations of T20-like 
antiviral HIV-1 drugs with improved potency and stability.    
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4.7. Figures 
 
 
 
 
 
 
Figure 4.1. Potency of membrane-impermeable inhibitors in TZM-bl cell line. 
 
(A) Neutralization of infectious HIV-1 particles by VRC03 antibody and Alexa-594-
VRC03. (B) Neutralization of infectious HIV-1 particles by b12 antibody and Alexa-594-
b12. (C) Inhibition on viral infection by T20. HIV-1 carrying EGFP-Vpr was used. Error 
bars are standard deviations from three independent replicates of the same experiments. 
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Figure 4.2. Classifying the location of virions inside, outside, or on cellular surface. 
 
(A) A representative confocal image of SupT1 cells inoculated for 2 hours with HIV-1 
carrying free EGFPs in the absence of T20. (B) A representative confocal image of SupT1 
cells inoculated for 2 hours with HIV-1 carrying free EGFPs in the presence of 1 µM T20. 
(C) Cellular membranes identified (red circles) by custom-written MATLAB. (D) Whole 
stacks of confocal images in a FOV with identifying cellular membrane and classifying the 
location of virions. A cell can be detected using edge detection method and basic 
morphology given sufficient contrast. Identified cellular membrane was further dilated by 
5 pixels and eroded by 1 pixel. Since fluorescent viral particles can be imaged more than 2 
stacks of confocal image, we identified all virions and relabeled them as unique virions. 
All overlapping virion regions were globally found based on the shortest centroid-to-
centroid distances and a virion on the slice having the strongest intensity were relabeld as 
a unique virion. 
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Figure 4.3. Quantitation of endocytosed virions in SupT1 cell line in the absence or 
presence of saturating concentration of T20. 
 
(A) Fraction of virion internalization with gag particles, which have no HIV-1 envelope on 
virion surface with different inoculation time points. Blue (no T20). Red (1 µM T20). (B) 
Fraction of virion internalization with HIV-1 having 0.1 µg NL4-3 envelope with different 
inoculation time points. Black (no T20). Purple (1 µM T20). (C) Fraction of virion 
internalization with HIV-1 carrying 1 µg NL4-3 envelope with different inoculation time 
points. Black (no T20). Green (1 µM T20). The location of virions can be analyzed as 
outside cells, inside cells, or on the cellular membrane. The fraction of virion 
internalization was calculated as a ratio of the number of virions inside cells to the total 
number of virions in a FOV. All virions were produced from 293T cells. MOP value was 
200 for all samples. Error bars are from 35 cells in the average from five different areas 
were collected for each data point.  
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Figure 4.4. Receptor-independent endocytosis with T-cell derived virions in SupT1 
cell line. 
 
Quantitation of endocytosed virions derived from Jurkat T cells in the absence or presence 
of saturating concentration of T20. (A) Fraction of virion internalization with gag particles, 
which have no HIV-1 envelope or HIV-1 carrying 1 µg NL4-3 envelope with 2 hours 
inoculation time points in the absence of T20. (B) Fraction of virion internalization with 
gag particles, which have no HIV-1 envelope or HIV-1 carrying 1 µg NL4-3 envelope with 
2 hours inoculation time points in the presence of 1 µM T20. MOP value was 200 for all 
samples. Error bars are from 30 cells in the average from five different areas were collected 
for each data point. 
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Figure 4.5. Effect of endocytosis inhibition by dynasore on T20 efficacy. 
 
(A) Measurement of productive infections with different concentrations of T20 in TZM-bl 
cells pretreated with 80 µM of dynasore. The mixture of HIV-1 with different 
concentrations of T20 was inoculated for 2 hours. Fraction of blue cells were singly 
normalized to no dynasore control. (B) Same experimental data as (A) was analyzed with 
a different way. Fraction of blue cells were respectively normalized to no dynasore without 
T20. Black (no dynasore, the concentration of DMSO was the same as 80 µM dynasore). 
Blue (80 µM dynasore). Error bars are standard deviations from three independent 
replicates of the same experiments. 
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Figure 4.6. Effect of endocytosis inhibition by dyn I K44A on T20 efficacy. 
 
(A) Measurement of productive infections with different concentrations of T20 in TZM-bl 
cells pretreated with 80 µM of dynasore. The mixture of HIV-1 with different 
concentrations of T20 was inoculated for 2 hours. Fraction of blue cells were singly 
normalized to pcDNA3.1(-) control. (B) Same experimental data as (A) was analyzed with 
a different way. Fraction of blue cells were respectively normalized to pcDNA3.1(-) 
without T20. Black (pcDNA3.1(-)). Red (non-tagged dyn I K44A from rat). Blue (HA-
tagged dyn I K44A from human). Error bars are standard deviations from three independent 
replicates of the same experiments. 
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 Figure 4.7. T20 efficacy in the presence of endocytosis inhibition by dynasore with 
different time points T20 added. 
(A) Measurement of productive infections with different time points T20 added in TZM-
bl cells pretreated with 80 µM of dynasore. Cells were inoculated with HIV-1 and 100 nM 
of T20 was added for each designated time within 2 hours inoculation. Fraction of blue 
cells were singly normalized to no dynasore control. (B) Same experimental data as (A) 
was analyzed with a different way. Fraction of blue cells were respectively normalized to 
no dynasore without T20. Black (no dynasore, the concentration of DMSO was the same 
as 80 µM dynasore). Blue (80 µM dynasore). Error bars are standard deviations from three 
independent replicates of the same experiments. 
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Figure 4.8. T20 efficacy in the presence of endocytosis inhibition by dyn I K44A 
with different time points T20 added. 
 
(A) Measurement of productive infections with different time points T20 added in TZM-
bl cells transfected with 2 µg of pcDNA3.1, non-tagged dyn I K44A (from rat), or HA-
tagged dyn I K44A (from human). Cells were inoculated with HIV-1 and 100 nM of T20 
was added for each designated time within 2 hours inoculation. Fraction of blue cells were 
singly normalized to pcDNA3.1(-) control. (B) Same experimental data as (A) was 
analyzed with a different way. Fraction of blue cells were respectively normalized to 
pcDNA3.1(-) without T20. Black (pcDNA3.1(-)). Blue (non-tagged dyn I K44A from rat). 
Red (HA-tagged dyn I K44A from human). Error bars are standard deviations from three 
independent replicates of the same experiments. 
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Chapter 5. 
 
Discussion of Results and Future Directions 
 
5.1. Overview of Results 
Cellular pathways for productive HIV-1 entry and molecular mechanisms of its 
inhibition have not been fully understood yet. Also, the characteristics of individual virion 
have not been extensively studied, but it recently turned out that virions in culture fluids 
show heterogeneous features in the number of envelope glycoproteins (1). In order to 
investigate the behaviors of virus including how it enters its target cell and where 
membrane fusion process for releasing virus genome occurs, it is necessary to fluorescently 
label virions. Furthermore, molecularly cloned HIV-1 that is capable of only a single round 
of infection (2, 3), called single-cycle replicative virion, offers a unique tool to address 
important questions related to the early event of viral infection, such as viral entry. Thus, 
we characterized single-cycle replicative, fluorescently-labeled HIV-1 in chapter 2. First of 
all, we established how to measure the concentration of infectious particles (Ci.p.) for 
measuring infectivity by taking an advantage of viral protein, Vpr, suppressing G2 cell 
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cycle (4). The infectivity was then optimized by varying several virus culture conditions. 
Among these culture variables, EGFP-Vpr plasmid input, virion harvest time, media 
replacement after transfection, and envelope plasmid input can all improve HIV-1 
infectivity by reducing the number of defective virions. We then visualized virions by 
tagging Vpr, a viral accessory protein physically associated with the virus core, with EGFP 
(5-7). Fluorescent-tagged virion using EGFP-Vpr fusion protein, which showed ~50% 
labeling efficiency, allows direct visualization of HIV-1. Although the imaging method 
cannot provide a direct conversion between the number of virion particles and the 
concentration of physical particles (Cp.p.) due to the potential presence of virions without 
EGFP, they were strongly correlated supporting p24 values as a measurement of viral Cp.p. 
in our imaging method. Furthermore, we characterized HIV-1 tagged with EGFP-Vpr in 
terms of size, mean intensity, and sum intensity distributions. Even though there was a 
trade-off effect between fluorescent intensity and infectivity, we were able to pick 0.15 
µg/ml of EGFP-Vpr plasmid input which results in the highest infectivity and reasonable 
intensity profiles amid the broad distribution of intensities. These studies help further 
investigate the mechanism of viral entry as well as develop deep understanding of 
individual HIV-1 virions.  
In chapter 3, first of all, we can clearly visualize HIV-1 virions colocalized with early 
endosomes. Also, the fraction of colocalization was comparable when using VSV-G 
pseudotyped virions. This suggests the localized HIV-1 inside early endosomes may go to 
further productive infections based on the fact that VSV-G is able to cause infections via 
receptor-dependent endocytosis (8). To examine the extent to which endocytosis leads to 
productive infection of HIV-1, we have used several inhibitors of dynamin to investigate 
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whether there is a correlation between the inhibition of HIV-1 infection and the inhibition 
of cell endocytosis. Transfection of TZM-bl indicator cells by dyn1 K44A, the dominant-
negative mutant of dynamin I, decreased HIV-1 infection by ~30%, which correlated with 
the decrease of endocytosis as monitored via transferrin uptake, suggesting that dynamin-
dependent endocytosis contributes to the productive infection of HIV-1. Furthermore, 
dynasore, a noncompetitive inhibitor of dynamin (9), inhibited HIV-1 infection in various 
cell lines, suggesting that endocytosis can indeed lead to productive infection, as revealed 
by the specific inhibition of HIV-1 infectivity by the dyn I K44A mutant. The specificity 
of inhibitors is critical for the interpretation of these data, and through this study we 
uncovered the off-target effect of dynasore. Our all inhibition data showed the partial 
inhibition on viral infection by blocking endocytosis due to cellular cytotoxicity with high 
concentrations of dynasore and chlorpromazine. However, there was no apparent 
difference in the extent of inhibition on viral infection between HIV-1 and VSV-G 
pseudotyped virion. This also suggests that endocytosis can indeed contribute to productive 
infection.  
Either direct fusion or endocytosis, there should be membrane fusion process 
between viral membrane and plasma or endosome membrane for viral productive infection 
(10, 11). Interestingly, endocytosed HIV-1 can be clearly observed in SupT1 cells even in 
the presence of saturating T20, suggesting that T20 may be endocytosed together with HIV-
1 and exerts its inhibitory effect inside an endosome. However, endocytosis may not be the 
only productive pathway for HIV-1 infection because all these inhibitions that we have 
observed appear to be partial, which is in sharp contrast to inhibition by T20.  T20, the 
membrane-impermeable inhibitor of HIV-1 fusion, potently inhibited HIV-1 infection in 
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all cell lines investigated in our studies. These results also suggest that endocytosed virions 
need to fuse with endosomal membrane for productive infection.  Therefore, we concluded 
receptor-dependent endocytosis contributes to the productive entry of HIV-1.  
Furthermore, some studies have suggested that endocytosis may allow virions to 
escape from the action of membrane-impermeable drugs (12, 13).  The conclusion that 
endocytosis can lead to productive infection of HIV-1 virions leads to our investigation in 
chapter 4: what is the impact of endocytosis on membrane impermeable drugs of HIV-
1? To address this question, we have tested both neutralizing antibodies and one of the 
fusion inhibitors, T20, and further focused on T20 to dissect the mechanisms of 
inhibition.  First of all, both antibodies and T20 can block viral infections close to 100%, 
indicating that these drugs are potent enough in vitro even though HIV-1 can establish 
productive infection through endocytosis, which was the conclusion from chapter 3. To 
test the hypothesis that endocytosis may allow virus to escape from membrane-
impermeable drugs, we have tested the effect of T20 on the internalization of HIV-1 by 
analyzing confocal images. To further investigate the impact of endocytosis on the efficacy 
of T20, we did titration of T20 and also varied the time of addition for T20 with regard to 
virion infection by TZM-bl cells, whose endocytic activity had been inhibited. These 
experiments showed that T20 doesn’t affect virion endocytosis and endocytosis has no 
apparent impact on T20 efficacy. It suggests that endocytosis does not offer a measurable 
advantage for virus to escape. Investigating the behavior and mechanism of T20 is 
fundamentally important for molecular understanding of HIV-1 entry as well as developing 
new generations of T20-like anti HIV-1 drugs having improved potency and stability.    
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5.2. Future Directions 
5.2.1. Correlation between only transfected cells with dyn I K44A and viral fusion 
Although we observed the correlation between the inhibition on endocytosis and the 
inhibition on viral productive infections by using dyn I K44A mutant and several inhibitors 
related to endocytosis, we are taking an approach as an ongoing experiment, which can 
improve our previous studies with several aspects: first of all, we observed partial 
inhibition on viral infection when seeking the correlation between the inhibition on 
dynamin-dependent endocytosis and viral infections in chapter 3; second, this specific 
correlation was observed in TZM-bl cells, which is an engineered HeLa cell line, not T 
cells, the natural target of HIV-1; finally, there is a possibility that the partial inhibition in 
sharp contrast to the complete inhibition by T20, might be due to the partial transfection 
efficiency. Thus, the approach we have taken is transfecting Jurkat cells with dyn I K44A-
mCherry, conducting beta-lactamase (BlaM) assay, which can quantitate the viral fusion 
events (14), and then analyze viral fusion events using only transfected cells by gating 
mCherry positive cells.   
 
5.2.2. Physiologically relevant primary CD4 T+ cells 
Productive viral entry might be different among cell lines or primary human cells. 
Our results showing that endocytosis contributes to viral infection would be more 
conclusive if the inhibition on endocytosis and inhibition on viral infection shows a strong 
correlation using primary human CD4+ T cells. Also, we were not able to block all 
functional dynamin molecules due to toxicity of dynasore and partial transfection 
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efficiency. In order to definitively assess the effect of dynamin-dependent endocytosis on 
viral infection, it would be required to knock down all three dynamin isoforms (15). 
 
5.2.3. Controversial conclusion regarding productive HIV-1 entry recently studied 
Although there have been extensive studies for productive HIV-1 entry, the 
conclusion from different research groups are still controversial. Also, it may be distinct 
with different virus spread modes, such as cell-to-cell transmission although there is a paper 
claiming that dynamin-dependent endocytosis is a main entry pathway in viral spread mode 
of cell-to-cell transmission (16). Recently, a research group claimed that productive HIV-
1 entry occurs predominantly at the plasma membrane in SupT1-R5, CEM-ss, and primary 
CD4+ T cells, with little, if any, contribution coming from endocytosed virions (17, 18). 
This is following up on their own published work, which had shown that endocytosis 
contributes to productive HIV-1 entry in HeLa cell-derived cell lines (19). This study 
mainly used the technique called temperature-arrested state (TAS) at 22°C, which can 
block membrane fusion, not endocytosis. Even though it has systematically used well-
controlled temperature system and different cell lines including primary cells, there is a 
possibility that productive viral entry is affected by TAS based on the fact that endocytosis 
is a dynamic process (20) and fusion events among endosomes containing virus or T20. 
Contrary to this observation, another research group has claimed that the visualization of 
single viral lipid/content transfer events under physiological conditions can reveal the HIV-
1 entry sites in lymphocytes and macrophages. Their approach is to distinguish between 
virus fusion with the PM and endosomes based on the extent of dilution of the viral lipid 
marker with single virus tracking (21). Therefore, in order to fully understand HIV-1 entry 
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mechanism, this areas of research needs more accumulation of other critical evidences, 
such as capturing diffusive signals from virion membrane fusion with more advance 
imaging techniques without interfering the normal functions of cells.  
  
5.2.4. The mechanism and location of T20 action 
Since T20 is membrane-impermeable, there are two possible explanations for the 
phenomena showing T20 potently inhibits viral infection. T20 can block HIV-1 infection 
at the site of action outside of the plasma membrane. Otherwise, it might be co-internalize 
with virus and exhibit its inhibitory action within an endosome. For T20, we found that 
HIV still undergoes endocytosis in the presence of saturating T20, suggesting the latter 
mechanism. However, one possibility for the first mechanism is that the events of virion 
endocytosis in the presence of T20 are all receptor-independent and nonspecific. The 
possible experiment will be the colocalization of virions with anti-CD4 in an endosome. 
Further colocalization studies using FITC-T20 and mCherry-labeled virus inside 
endosomes at single-molecule resolution will definitely test the hypothesis that T20 might 
be able to act its inhibitory effect inside endosomes.  
 
5.3. Concluding Remarks 
On the basis of the findings presented in this thesis, characterizing the features of 
individual HIV-1 particles helps understand the events of virus infection as well as data 
interpretation. First of all, one of the mechanisms explaining the low infectivity of HIV-1 
was revealed that there are many defective virus particles in virus pool (22, 23). Another 
potential mechanism is the low number of envelope spikes on virion surface, which may 
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suppress the immune response making a difficulty in developing HIV vaccines (24, 25). 
Second, there was a trade-off effect between fluorescent intensity and infectivity, however, 
the distribution of intensity was pretty broad, suggesting individual HIV-1 particles have 
heterogeneity in terms of protein compositions or other features (1). Lastly, the labeling 
efficiency was around 50%, meaning the rest of particles are not fluorescent. This issue 
should be taken care of when interpreting data for fluorescent imaging and inhibition assays. 
In order to overcome the partial labeling efficiency as well as make it more natural 
conditions, using label-free virus with optical biosensors might be a good strategy to study 
nanoparticles, such as HIV-1, or other viruses (26).   
In chapter 3 and chapter 4, our results suggest that endocytosis contributes to HIV-1 
productive entry. The phenomena were not coming from virus envelopes from different 
strains, or methods for facilitating virus binding to cell surface. Our conclusions may be 
different with other cell lines, or different infection environment, such as cell-to-cell 
transmission. However, a recent study also showed that HIV-1 virions enter cells via 
dynamin-dependent endocytosis during cell-to-cell transmission (16). The both 
conclusions that endocytosis contributes to HIV-1 productive entry and there is a negligible 
impact of endocytosis on T20 efficacy help understand viral pathogenesis and eventually 
improve the development of antiviral drugs. 
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